<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2909245967
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2007
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        TORVACOL 40MG F.C. TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ATORVASTATIN CALCIUM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        86.9
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 1055]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Dallah Health Care Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C10AA05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><br />IT IS USED FOR TORVACOL belongs to a group of medicines known as statins, which are lipid (fat) regulating medicines. TORVACOL is used to lower lipids known as cholesterol and triglycerides in the blood when a low fat diet and life style changes on their own have failed. If you are at an increased risk of heart disease, TORVACOL tablets can also be used to reduce such risk even if your cholesterol levels are normal. You should maintain a standard cholesterol lowering diet during treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>□ If you are hypersensitive (allergic) to Atorvastatin or any of the other ingredients of TORVACOL (listed in section 6) □ If you have or have ever had a disease which affects the liver. □ If you have had any unexplained abnormal blood tests for liver function. □ If you are a woman able to have children and not using reliable contraception. □ If you are pregnant or trying to become pregnant. □ If you are breast-feeding. □ If you use the combination of glecaprevir/ pibrentasvir in the treatment of hepatitis C. Take special care with TORVACOL: Talk to your doctor, pharmacist or nurse before taking TORVACOL: □ If you have severe respiratory failure □ If you are taking or have taken in the last 7 days a medicine called fusidic acid, (a medicine for bacterial infection) orally or by injection. The combination of fusidic acid and TORVACOL can lead to serious muscle problems (rhabdomyolysis) □ If you had a previous stroke with bleeding into the brain, or have small pockets of fluid in the brain from previous strokes. □ If you have kidney problems. □ If you have an under-active thyroid gland (hypothyroidism). □ If you have had repeated or unexplained muscle aches or pains, a personal history or family history of muscle problems. □ If you have had previous muscular problems during treatment with other lipid-lowering medicines (e.g. other &ldquo;-statin&rdquo; or &ldquo;-fibrate&rdquo; medicines). □ If you regularly drink a large amount of alcohol □ If you have a history of liver disease. □ If you are older than 70 years. □ If you have or have had myasthenia (a disease with general muscle weakness including in some cases muscles used when breathing), or ocular myasthenia (a disease causing eye muscle weakness) as statins may sometimes aggravate the condition or lead to the occurrence of myasthenia (see section 4). - If any of these apply to you, your doctor will need to carry out a blood test before and possibly during your TORVACOL treatment to predict your risk of muscle related side effects. The risk of muscle related side effects e.g. rhabdomyolysis is known to increase when certain medicines are taken at the same time (see Section 2&quot; Taking other medicines with TORVACOL&quot;). - Also tell your doctor or pharmacist if you have a muscle weakness that is constant. Additional tests and medicines may be needed to diagnose and treat this. - While you are on this medicine your doctor will monitor you closely if you have diabetes or are at risk of developing diabetes. You are likely to be at risk of developing diabetes if you have high levels of sugars and fats in your blood, are overweight and have high blood pressure. Taking other medicines with TORVACOL: Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. There are some medicines that may change the effect of TORVACOL tablets or their effect may be changed by TORVACOL tablets. This type of interaction could make one or both of the medicines less effective. Alternatively it could increase the risk or severity of side-effects, including the important muscle wasting condition known as rhabdomyolysis described in Section 4. □ Medicines used to alter the way your immune system works, e.g. cyclosporine □ Certain antibiotics or antifungal medicines, e.g. erythromycin, clarithromycin, telithromycin, ketoconazole, itraconazole, voriconazole, fluconazole, posaconazole, rifampin, fusidic acid. □ Other medicines to regulate lipid levels, e.g. gemfibrozil, other fibrates, colestipol □ Some calcium channel blockers used for angina or high blood pressure,e.g. amlodipine, diltiazem, medicines to regulate your heart rhythm e.g. digoxin, verapamil, amiodarone. □ Letermovir, a medicine that helps stop you from getting ill from cytomegalovirus □ Medicines used in the treatment of HIV e.g. ritonavir, lopinavir, atazanavir, indinavir, darunavir, the combination of tipranavir/ritonavir etc. □ Some medicines used in the treatment of hepatitis C e.g. telaprevir, boceprevir and the combination of elbasvir/ grazoprevir, ledipasvir/ sofosbuvir. □ Other medicines known to interact with TORVACOL tablets include ezetimibe (which lowers cholesterol), warfarin (which reduces blood clotting), oral contraceptives, stiripentol (an anticonvulsant for epilepsy), cimetidine (used for heartburn and peptic ulcers), phenazone (a painkiller), colchicine (used to treat gout) and antacids (indigestion products containing aluminum or magnesium) □ Medicines obtained without a prescription: St John&rsquo;s Wort. □ If you need to take oral fusidic acid to treat a bacterial infection you will need to temporarily stop using this medicine. Your doctor will tell you when it is safe to restart TORVACOL. Taking TORVACOL with fusidic acid may rarely lead to muscle weakness, tenderness or pain (rhabdomyolysis). See more information regarding rhabdomyolysis in section 4. Taking TORVACOL with food and drink: See Section 3 for instructions on how to take TORVACOL tablets. Please note the following: □ Grapefruit juice: Do not take more than one or two small glasses of grapefruit juice per day because large quantities of grapefruit juice can change the effects of TORVACOL tablets. □ Alcohol: Avoid drinking too much alcohol while taking this medicine. See Section 2 &ldquo;Take special care with TORVACOL tablets&rdquo; for details Pregnancy and breastfeeding: Pregnancy □ Safety in pregnant women has not been established. □ The decision to take TORVACOL during pregnancy is based on the doctor opinion when taking into account the benefits and risks when using TORVACOL during pregnancy. □ Observational studies did not find an increase in major birth defects associated with the use of statins during pregnancy. Breast-feeding □ The safety of TORVACOL tablets during pregnancy and breast-feeding has not yet been proven. □ Do not take TORVACOL tablets if you are breast-feeding. Ask your doctor or pharmacist for advice before taking any medicine. Driving and using machines: Normally this medicine does not affect your ability to drive or operate machines. However, do not drive if this medicine affects your ability to drive. Do not use any tools or machines if your ability to use them is affected by this medicine. Important information about some of the ingredients of TORVACOL: This medicine contains lactose. If you have been told by your doctor that you have an intolerance to some sugars, please contact your doctor before taking this medicine</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>□ Before starting treatment, your doctor will place you on a low-cholesterol diet, which you should maintain also during therapy with TORVACOL tablets. □ The usual starting dose of TORVACOL is 10 mg once a day in adults and children aged 10 years or older. This may be increased if necessary by your doctor until you are taking the amount you need. □ Your doctor will adapt the dose at intervals of 4 weeks or more. □ The maximum dose of TORVACOL tablets is 80 mg once a day. □ TORVACOL tablets should be swallowed whole with a drink of water, and can be taken at any time of day, with or without food. However, try to take your tablet at the same time every day. □ Always take TORVACOL tablets exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure. □ The duration of treatment with TORVACOL tablets is determined by your doctor. Please ask your doctor if you think that the effect of TORVACOL tablets is too strong or too weak. If you take more TORVACOL than you should: If you accidently take too many TORVACOL tablets (more than your usual daily dose), contact your doctor or nearest hospital for advice. If you forget to take TORVACOL: If you forget to take a dose, just take your next scheduled dose at the correct time. Do not take a double dose to make up for a forgotten dose. If you stop taking TORVACOL: If you have any further questions on the use of this medicine or wish to stop your treatment, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, TORVACOL can cause side effects, although not everybody gets them. If you experience any of the following serious side effects, stop taking your tablets and tell your doctor immediately or go to the nearest hospital accident and emergency department. Rare (may affect up to 1 in 1,000 people): □ Serious allergic reaction which causes swelling of the face, tongue and throat that can cause great difficulty in breathing. □ Serious illness with severe peeling and swelling of the skin, blistering of the skin, mouth, eyes genitals and fever. Skin rash with pink-red blotches especially on palms of hands or soles of feet which may blister. □ Muscle weakness, tenderness, pain, rupture or red-brown discolouration of urine and particularly, if at the same time, you feel unwell or have a high temperature it may be caused by an abnormal muscle breakdown (rhabdomyolysis). The abnormal muscle breakdown does not always go away, even after you have stopped taking atorvastatin, and it can be life-threatening and lead to kidney problems. Very rare (may affect up to 1 in 10,000 people): □ If you experience problems with unexpected or unusual bleeding or bruising, this may be suggestive of a liver complaint. You should consult your doctor as soon as possible. □ Lupus- like disease syndrome (including rash, joint disorders and effects on blood cells). Other possible side effects with TORVACOL tablets: Common (may affect up to 1 in 10 people): □ Inflammation of the nasal passages, pain in the throat, nose bleed. □ Allergic reactions. □ Increases in blood sugar levels (if you have diabetes continue careful monitoring of your blood sugar levels), increase in blood creatine kinase. □ Headache. □ Nausea, constipation, wind, indigestion, diarrhea. □ Joint pain, muscle pain and back pain. □ Blood test results that show your liver function can become abnormal. Uncommon (may affect up to 1 in 100 people): □ Anorexia (loss of appetite), weight gain, decreases in blood sugar levels (if you have diabetes you should continue careful monitoring of your blood sugar levels). □ Having nightmares, insomnia. □ Dizziness, numbness or tingling in the fingers and toes, reductions of sensation to pain or touch, change in sense of taste, loss of memory. □ Blurred vision. □ Ringing in the ears and/or head. □ Vomiting, belching, abdominal pain upper and lower, pancreatitis (inflammation of the pancreas leading to stomach pain). □ Hepatitis (liver inflammation). □ Rash, skin rash and itching, hives, hair loss □ neck pain, muscle fatigue □ Fatigue, feeling unwell, weakness, chest pain, swelling especially in the ankles (Oedema), raised temperature. □ Urine test that is positive for white blood cells. Rare (may affect up to 1 in 1000 people): □ Visual disturbance □ Unexpected bleeding or bruising □ Cholestasis (yellowing of the skin and whites of the eyes) □ Tendon injury. Very rare (may affect up to 1 in 10,000 people): □ An allergic reaction - symptoms may include sudden wheezing and chest pain or tightness, swelling of the eyelids, face, lips, mouth, tongue or throat, difficulty breathing, collapse. □ Hearing loss. □ Gynecomastia (breast enlargement in men). Not known (frequency cannot be estimated from the available data): □ Muscle weakness that is constant. □ Myasthenia gravis (a disease causing general muscle weakness including in some cases muscles used when breathing). Ocular myasthenia (a disease causing eye muscle weakness). Talk to your doctor if you experience weakness in your arms or legs that worsens after periods of activity, double vision or drooping of your eyelids, difficulty swallowing, or shortness of breath. Possible side effects reported with some statins (medicines of the same type): □ Sexual difficulties □ Depression □ Breathing problems including persistent cough and/or shortness of breath or fever. □ Diabetes. This is more likely if you have high levels of sugars and fats in your blood, are overweight and have high blood pressure. Your doctor will monitor you while you are taking this medicine</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>□ Keep out of the reach and sight of children. □ Do not store above 30&deg;C, protected from humidity. □ Do not use TORVACOL after the expiry date which is stated on the carton and on the blister, after (EXP).Date. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environmen</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What TORVACOL contains: The active substance is Atorvastatin as Atorvastatin Calcium. Each TORVACOL 10, 20 and 40 Tablet contains Atorvastatin 10, 20 and 40 mg, respectively, as Atorvastatin Calcium. The other ingredients are: Microcrystalline Cellulose, Calcium Carbonate, Lactose Monohydrate, Hydroxypropyl Cellulose, Croscarmellose Sodium, Magnesium Stearate, Hydroxypropyl Methyl Cellulose,Titanium Dioxide, Polyethylene Glycol. What TORVACOL looks like and contents of the pack: □ TORVACOL 10 Tablets are white to off-white, circular shallow biconvex film coated tablet debossed with &ldquo;TV10&rdquo; on one side and plain on the other side. □ TORVACOL 20 Tablets are white to off-white, circular shallow biconvex film coated tablets debossed with &ldquo;TV 20&rdquo; on one side, and plain on the other side. □ TORVACOL 40 Tablets are white to off-white oblong shallow biconvex film coated tablet debossed with &ldquo;TV 40&rdquo; on one side and plain on the other side. □ Boxes of 30 blistered tablets of TORVACOL 10 Tablets. □ Boxes of 1480 blistered tablets of TORVACOL 10 Tablets. □ Boxes of 30 blistered tablets of TORVACOL 20 Tablets. □ Boxes of 30 blistered tablets of TORVACOL 40 Tablets</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                The active substance is Atorvastatin as 
Atorvastatin Calcium. Each TORVACOL 
10, 20 and 40 Tablet contains Atorvastatin 10, 20 and 40 mg, respectively, as 
Atorvastatin Calcium.
The other ingredients are: Microcrystalline Cellulose, Calcium Carbonate, 
Lactose Monohydrate, Hydroxypropyl 
Cellulose, Croscarmellose Sodium, 
Magnesium Stearate, Hydroxypropyl 
Methyl Cellulose,Titanium Dioxide, 
Polyethylene Glycol
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>□ TORVACOL 10 Tablets are white to off-white, circular shallow biconvex film coated tablet debossed with &ldquo;TV10&rdquo; on one side and plain on the other side. □ TORVACOL 20 Tablets are white to off-white, circular shallow biconvex film coated tablets debossed with &ldquo;TV 20&rdquo; on one side, and plain on the other side. □ TORVACOL 40 Tablets are white to off-white oblong shallow biconvex film coated tablet debossed with &ldquo;TV 40&rdquo; on one side and plain on the other side. □ Boxes of 30 blistered tablets of TORVACOL 10 Tablets. □ Boxes of 1480 blistered tablets of TORVACOL 10 Tablets. □ Boxes of 30 blistered tablets of TORVACOL 20 Tablets. □ Boxes of 30 blistered tablets of TORVACOL 40 Tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                September 2023

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>تورڤاكول ینتمي إلى مجموعة من الأدویة تعرف بالستاتین وھي أدویة منظمة للدھون. یستخدم تورڤاكول لتخفیض نسبة الدھون مثل الكولیستیرول و الدھون ثلاثیة الغلیسراید في الدم، عند عدم الحصول على النتائج المطلوبة من اتباع نظام غذائي و إحداث تغیرات في نمط الحیاة بھدف تقلیل نسبة الدھون. إذا كنت تعاني من خطر متزاید لأمراض القلب، یمكن أیضا استخدام أقراص تورڤاكول للحد من ھذه المخاطر حتى لو كانت مستویات الكولسترول طبیعیة. یجب الالتزام بنظام غذائي منخفض الدھون خلال فترة العلاج.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><br />□ إذا كنت تعاني من حساسیة لأتورڤاستاتین، أو أي من مكونات تورڤاكول الأخرى (المدرجة في القسم ٦). □ إذا كان لدیك أو سبق أن عانیت من مرض یؤثر على الكبد. □ إذا كان لدیك أي فحوصات دم غیر طبیعیة غیر مبررة لوظائف الكبد. □ إذا كنت امرأة قادرة على إنجاب الأطفال ولا تستخدم وسائل منع الحمل الموثوقة. ً أو تحاولین الحمل. □ إذا كنت حاملا □ إذا كنت مرضعة. □ إذا كنت تستخدم مزیج من جلیكابریفیر/ بیبرنتاسفیر في علاج التھاب الكبد نوع سي. الاحتیاطات عند استعمال تورڤاكول: تحدث إلى طبیبك، الصیدلي أو الممرض قبل تناول تورڤاكول: □ إذا كان لدیك فشل شدید في الجھاز التنفسي □ إذا كنت تتناول أو تناولت في الأیام السبعة الماضیة دواء یسمى حمض الفیوسیدیك، (دواء للعدوى البكتیریة) عن طریق الفم أو عن طریق الحقن. مزیج حمض الفوسیدیك وتورڤاكول یمكن أن یؤدي إلى مشاكل عضلیة خطیرة (انحلال الربیدات). ً من جلطة دماغیة مع نزیف في □ إذا عانیت سابقا الدماغ ، أو جیوب صغیرة من السوائل في الدماغ سببتھا جلطات دماغیة سابقة. □ إذا كنت تعاني من مشاكل في الكلى. □ إذا كنت تعاني من قصور في الغدة الدرقیة. □ إذا كنت تعاني من آلام متكررة و غیر مفسرة في العضلات. أو إذا كان لدیك تاریخ شخصي أو عائلي في مشاكل العضلات. ً من مشاكل في العضلات خلال □ إذا عانیت سابقا فترة تناولك لأحد الأدویة الخافضة للدھون (أدویة أخرى تنتمي إلى مجموعة الستاتین أو مجموعة الفایبرات). □ إذا كنت تشرب الكحول بكمیات كبیرة و بشكل منتظم. □ إذا كان لدیك تاریخ من أمراض الكبد. .ً □ إذا كنت تبلغ من العمر أكثر من ۷۰ عاما ً بالوھن العضلي □ إذا كنت تعاني أو كنت مصابا (مرض مع ضعف عام للعضلات بما في ذلك في بعض الحالات العضلات المستخدمة عند التنفس)، أو الوھن العضلي العیني (مرض یسبب ضعف ً عضلات العین)، فقد تؤدي مجموعة الستاتین أحیانا إلى تفاقم الحالة أو تؤدي إلى حدوث الوھن العضلي (انظر القسم ٤). - إذا كان أي من المذكور أعلاه ینطبق علیك، فقد یحتاج طبیبك للقیام بفحوصات دم قبل و أثناء فترة تناولك تورڤاكول للتنبؤ بأخطار الآثار الجانبیة المرتبطة بالعضلات. ومن المعروف أن خطر الأثار الجانبیة المرتبط بالعضلات على سبیل المثال انحلال الربیدات تزداد عندما تؤخذ بعض الأدویة في نفس الوقت مع تورڤاكول (انظر القسم &quot;۲&quot; &quot;تناول أدویة أخرى مع تورڤاكول&quot;). ً أخبر طبیبك أو الصیدلي أیضا إذا كنت تعاني من ضعف عضلي مستمر. قد تكون ھناك حاجة إلى فحوصات إضافیة وأدویة لتشخیص وعلاج ھذا - أثناء تناولك لھذا الدواء، سیراقبك طبیبك عن ًا بداء السكري أو معرض كثب إذا كنت مصاب للإصابة بمرض السكري. من المحتمل أن تكون ً معرضا لخطر الإصابة بمرض السكري إذا كان لدیك مستویات عالیة من السكریات والدھون في دمك، زیادة في الوزن وتعاني من ارتفاع ضغط الدم. تناول أدویة أخرى مع تورڤاكول: أخبر طبیبك أو الصیدلي إذا كنت تتناول أو تناولت ً مؤخرا أو قد تأخذ أي ادویة أخرى. ھناك بعض الأدویة التي قد تغیر من تأثیر تورڤاكول أو قد یتغیر تأثیرھا أثناء تناولھا مع تورڤاكول. قد یؤدي ھذا التداخل إلى تقلیل فعالیة أحد الأدویة أو كلاھما. أو قد تؤدي ھذه التداخلات إلى زیادة شدة الآثار الجانبیة، و یشمل ذلك الأثر الجانبي المرتبط بتلف العضلات المعروف بانحلال الربیدات (الموضحة في القسم ٤). □ الأدویة التي تستخدم لتغییر آلیة عمل جھاز المناعة، مثال: سیكلوسبورین. □ بعض المضادات الحیویة و مضادات الفطریات، على سبیل المثال، اریثرومیسین، كلاریثرومیسین، تیلیثرومیسین، كیتوكونازول، ایتراكونازول، ڤوریكونازول، فلوكونازول، بوساكونازول، ریفامبین، حمض الفیوسیدیك. □ الأدویة الأخرى التي تستخدم لتنظیم مستویات الدھون، على سبیل المثال جیمفیبروزیل، أنواع أخرى من الفایبریت، كولیستیبول. □ بعض حاصرات قنوات الكالسیوم المستخدمة لعلاج الذبحة وارتفاع ضغط الدم، على سبیل المثال أملودیبین، دیلتیازیم. و الأدویة التي تستخدم لتنظیم ضربات القلب، على سبیل المثال: دیجوكسین، ڤیرابامیل، أمیودارون. □ لیتیرموفیر، دواء یساعد على منعك من الإصابة بالفیروس المضخم للخلایا □ الأدویة المستخدمة في علاج فیروس نقص المناعة البشریة على سبیل المثال. ریتونافیر، لوبینافیر، أتازانافیر، إندینافیر، دارونافیر، مزیج من تیبرانافیر/ ریتونافیر إلخ. □ بعض الأدویة المستخدمة في علاج التھاب الكبد سي مثل تیلابریفیر، بوسیبریفیر ومزیج من جلیكابریفیر/ بیبرنتاسفیر، لیدیباسفیر/ سوفوسبوفیر. □ أدویة أخرى معروفة بتداخلھا مع أقراص تورڤاكول وتشمل: إزیتمایب (یعمل على تخفیض نسبة الكولیسترول)، وارفارین (یقلل من الجلطات الدمویة)، موانع الحمل المأخوذة عن طریق الفم، ستیریبنتول (مضاد الاختلاج لعلاج الصرع )، السیمیتیدین (یستخدم لعلاج الحرقة و القرحة َم)، كولشسین الھضمیة)، فینازون (مسكن للأل (یستخدم لعلاج النقرس) ومضادات الحموضة (مركبات غیر قابلة للھضم تحتوي على الألمنیوم والمغنیسیوم). □ الأدویة التي یتم تناولھا بدون وصفة طبیة: نبتة سانت جون. □ إذا كنت بحاجة إلى تناول حمض الفیوسیدیك عن طریق الفم لعلاج عدوى بكتیریة، فستحتاج إلى ًا. سیخبرك التوقف عن استخدام ھذا الدواء مؤقت طبیبك عندما یكون من الآمن إعادة تناول تورڤاكول. نادرا ما یؤدي تناول تورڤاكول مع حمض الفیوسیدیك إلى ضعف العضلات، الرقة أو الألم (انحلال الربیدات). انظر المزید من المعلومات حول انحلال الربیدات في القسم .٤ تناول تورڤاكول مع الطعام والشراب: انظر القسم ۳ لمعرفة كیفیة أخذ أقراص تورڤاكول. یرجى ملاحظة ما یلي: □ عصیر جریب فروت: لا تأخذ أكثر من كأس صغیر أو كأسین صغیرین من عصیر الجریب فروت في الیوم لأن الكمیات الكبیرة من ھذا العصیر قد یغیر من التأثیر الفعال لأقراص تورڤاكول. □ الكحول: تجنب شرب الكثیر من الكحول أثناء تناولك تورڤاكول (لمزید من المعلومات انظر إلى القسم ۲ &quot;الاحتیاطات عند استعمال تورڤاكول&quot;). الحمل والارضاع: الحمل □ لم یتم إثبات مأمونیة الإستخدام في النساء الحوامل. □ یعتمد قرار تناول تورڤاكول أثناء الحمل على رأي الطبیب عند الأخذ في الاعتبار الفوائد والمخاطر عند إستخدام تورڤاكول أثناء الحمل. □ لم تجد الدراسات القائمة على الملاحظة زیادة في العیوب الخلقیة الرئیسیة المرتبطة باستخدام الستاتینات أثناء الحمل. الارضاع □ لم یثبت بعد سلامة استخدام تورڤاكول عند الحوامل و المرضعات . □ یمنع إعطاء تورڤاكول للأمھات المرضعات. إسألي طبیبك أو الصیدلاني قبل تناول أي دواء. قیادة السیارات واستعمال الآلات: لا یؤثرتورڤاكول عادة على قدرتك على القیادة أو تشغیل الآلات، لكن تأكد من أنك تعرف كیفیة تأثیر ھذا الدواء علیك قبل قیادة السیارة. لا تستخدم أي أدوات أو آلات إذا تأثرت قدرتك على استخدامھا من قبل ھذا الدواء. معلومات ھامة حول بعض مكونات تورڤاكول: یحتوي ھذا الدواء على اللاكتوز. إذا أخبرك طبیبك بأنك لا تستطیع تحمل بعض أنواع السكریات، فإنھ یجب علیك استشارة طبیبك قبل تناول ھذا الدواء</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>.۳ طریقة استخدام تورڤاكول □ قبل استخدام العلاج، سوف یقوم طبیبك بوضع نظام غذائي منخفض الكولیسترول و یجب علیك المحافظة علیھ أثناء تناولك أقراص تورڤاكول. □ الجرعة الاعتیادیة لأقراص تورڤاكول لدى المرضى البالغین و الأطفال البالغین من العمر أكثر من ۱۰ سنوات ھي ۱۰ ملغم في الیوم. □ یمكن زیادة الجرعة إذا لزم الأمر من قبل الطبیب حتى تصل إلى الجرعة التي تحتاجھا. □ سوف یقوم طبیبك بضبط الجرعة على فترات مكونة من ٤ أسابیع أو أكثر. □ الجرعة القصوى من تورڤاكول ھي ۸۰ ملغم مرة واحدة في الیوم. □ تبلع أقراص تورڤاكول مع الماء و یمكن أخذه في أي وقت من الیوم مع أو بدون الطعام وحاول .ً أن یكون في نفس الوقت یومیا □ یجب علیك الإلتزام بتعلیمات الطبیب في كیفیة أخذ الدواء. إذا لم تكن متأكد، علیك استشارة الطبیب أو الصیدلاني. □ سیحدد لك طبیبك المدة اللازمة للعلاج باستخدام أقراص تورڤاكول. یرجى إخبار طبیبك إذا كنت ترى أن تأثیر .ً ً أو ضعیف جدا تورڤاكول قوي جدا إذا تناولت تورڤاكول أكثر مما یجب: اذا تناولت الكثیر من تورڤاكول (أكثر من الجرعة المقررة) فإن علیك التحدث إلى طبیبك أو الذھاب .ً إلى المستشفى مباشرة إذا نسیت تناول تورڤاكول: إذا نسیت تناول الجرعة، فإن علیك الانتظار حتى موعد الجرعة التالیة الواجبة. لا تتناول جرعة مضاعفة لتعویض الجرعة المنسیة. إذا توقفت عن تناول تورڤاكول: إذا كان لدیك أي أسئلة أخرى حول استخدام ھذا الدواء أو ترغب في التوقف عن العلاج، إسأل طبیبك أو الصیدلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p><br />كغیره من الأدویة، فقد یسبب تورڤاكول آثارا ،ً بالرغم من أنھا لاتحدث للجمیع. لذلك من جانبیة المھم أن تكون على علم بھذه الآثار الجانبیة. إذا كنت تواجھ أي من التأثیرات الجانبیة التالیة، توقف عن أخذ أقراص تورڤاكول وأخبر طبیبك على الفور اذھب إلى أقرب مستشفى وقسم الطوارئ. الاثار الجانبیة النادرة (قد تؤثر على ما یصل إلى شخص واحد من ۱۰۰۰ شخص): □ حساسیة شدیدة تسبب تورم في الوجھ، اللسان و الحلق و قد تسبب صعوبات كبیرة في التنفس. □ المرض الشدید مع تقشیر وتورم في الجلد، ظھور تقرحات في الجلد، الفم، العینین والأعضاء التناسلیة و حمى. طفح جلدي مع بقع حمراء- وردیة اللون خاصة في راحتي الیدین أو باطن القدمین قد تكون نفطة. □ ضعف، إیلام، ألم، تمزق العضلات، أو تغیر لون البول إلى اللون الأحمر والبني، وخاصة إذا شعرت في نفس الوقت بتوعك أو ارتفاع درجة الحرارة، فقد یكون ذلك بسبب انھیار عضلي غیر طبیعي (انحلال الربیدات). لا یختفي الانھیار ً العضلي غیر الطبیعي دائما، حتى بعد التوقف عن تناول أتورفاستاتین، ویمكن أن یھدد الحیاة ویؤدي إلى مشاكل في الكلى. ً (قد تؤثر على ما یصل إلى آثار جانبیة نادرة جدا شخص واحد من ۱۰۰۰۰ شخص): □ إذا عانیت من نزیف غیر اعتیادي أو غیر متوقع ً على مشاكل في أو تكدم ، فقد یكون ذلك مؤشرا الكبد. لذلك یجب علیك استشارة الطبیب في أقرب وقت ممكن. □ متلازمة مرض شبیھ بمرض الذئبة (بما في ذلك الطفح الجلدي، اضطرابات المفاصل وتأثیراتھا على خلایا الدم). الآثار الجانبیة الأخرى المحتملة لأقراص تورڤاكول: الآثار الجانبیة الشائعة (قد تؤثر على ما یصل إلى شخص واحد من ۱۰ أشخاص): □ التھاب في الممرات الأنفیة، ألم في الحلق، نزیف في الأنف. □ تفاعلات حساسیة □ ازدیاد مستوى السكر في الدم (إذا كنت تعاني من مرض السكري یجب علیك المراقبة المستمرة لمستویات السكر في الدم )، ارتفاع انزیم الكریاتین كیناز في الدم. □ صداع □ غثیان، إمساك، ریح، عسر الھضم، إسھال □ آلام مفاصل، آلام عضلات وآلام الظھر □ فحوصات دم تظھر أن وظیفة الكبد لدیك غیر طبیعیة الآثار الجانبیة غیر الشائعة (قد تؤثر على ما یصل إلى شخص واحد من ۱۰۰ شخص): □ فقدان الشھیة، زیادة الوزن، وانخفاض مستوى السكر في الدم (إذا كنت تعاني من مرض السكري یجب علیك المراقبة المستمرة لمستویات السكر في الدم). □ المعاناة من الكوابیس، الأرق. □ دوخة، خدر أو وخز في أصابع الیدین والقدمین، انخفاض الإحساس بالألم أو اللمس، تغییر في حاسة الذوق، و فقدان في الذاكرة □ عدم وضوح الرؤیة □ الرنین في الأذنین و/ أو الرأس □ القيء، التجشؤ، ألم في المنطقة العلویة أو السفلیة للبطن، التھاب البنكریاس (التھاب البنكریاس یؤدي إلى آلام في المعدة) □ التھاب الكبد □ طفح، طفح جلدي مع حكة، شرى، فقدان الشعر □ آلام الرقبة، تعب بالعضلات □ تعب، الشعور بالإعیاء، ضعف، ألم في الصدر، تورم خاصة في الكاحلین (وذمة) و ارتفاع في درجة الحرارة. □ فحص بول تكون فیھ خلایا الدم البیضاء إیجابیة. الآثار الجانبیة النادرة (قد تؤثر على ما یصل إلى شخص واحد من ۱۰۰۰ شخص): □ الاضطرابات البصریة □ نزیف أو كدمات غیر متوقعة □ ركود صفراوي (اصفرار الجلد وبیاض العینین) □ اصابة في الوتر ً (قد تؤثر على ما یصل إلى آثار جانبیة نادرة جدا شخص واحد من ۱۰۰۰۰ شخص): □ تفاعلات حساسیة (و تشمل الأعراض أزیز مفاجئ، ألم في الصدر أو ضیق، تورم في الجفن ، الوجھ، الشفاه، الفم، اللسان أو الحلق، صعوبة في التنفس والضعف الشدید ). □ فقدان السمع □ التثدي (تضخم الثدي عند الرجال) آثار جانبیة غیر معروفة (لا یمكن تقدیر تكرار حدوثھا من البیانات المتاحة): □ ضعف عضلي ثابت. □ الوھن العضلي الوبیل (مرض یسبب ضعف عام للعضلات بما في ذلك في بعض الحالات العضلات المستخدمة في عملیة التنفس). الوھن العضلي العیني (مرض یسبب ضعف عضلات العین). تحدث إلى طبیبك إذا كنت تعاني من ضعف في ً بعد فترات من ذراعیك أو ساقیك یزداد سوءا النشاط، ازدواج الرؤیة أو تدلي الجفون، صعوبة البلع أو ضیق التنفس. الآثار الجانبیة المحتملة التي ذكرت عند استخدام بعض أنواع الستاتین (أدویة من نفس النوع): □ الصعوبات الجنسیة □ الاكتئاب □ مشاكل بالتنفس تشمل السعال المستمر و/أو ضیق في التنفس وارتفاع درجة الحرارة □ مرض السكري. من المحتمل أن تكون معرض لخطر الإصابة بمرض السكري إذا كان لدیك مستویات عالیة من السكر والدھون في دمك وتعاني من زیادة في الوزن وارتفاع ضغط الدم. سیقوم طبیبك بمراقبتك أثناء تناولك لھذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>یحفظ بعیدا □ لا یحفظ بدرجة حرارة أعلى من &deg;۳۰م، محمي من الرطوبة. □ لا ینبغي استعمال تورڤاكول بعد تاریخ انتھاء الصلاحیة الموجود على العلبة وعلى شریط الدواء. □ لا ینبغي التخلص من الأدویة من خلال میاه الصرف الصحي أو المنزلي. اسأل الصیدلاني عن كیفیة التخلص من الأدویة التي لم تعد مطلوبة. سوف تساعد ھذه الاجراءات على حمایة البیئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة ھي أتورڤاستاتین على ھیئة أتورڤاستاتین الكالسیوم. كل قرص من أقراص تورڤاكول ،۱۰ ۲۰ و٤۰ یحتوي على ۱۰ ملغم۲۰، ملغم و٤۰ ملغم على التوالي من أتورڤاستاتین على ھیئة أتورڤاستاتین الكالسیوم. □ المكونات الأخرى ھي: سلولوز بلوري مكروي، كربونات الكالسیوم، لاكتوز مونوھیدرات، ھیدروكسي بروبیل سلولوز، صودیوم كروسكارمیلوز، ستیارات المغنیسیوم، ھیدروكسي بروبیل میثیل سلولوز، ثنائي أكسید التیتانیوم، بولي إیثیلین غلیكول.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>□ أقراص تورڤاكول ۱۰ ھي أقراص بیضاء إلى سكریة اللون مستدیرة مسطحة ثنائیة التحدب مغلفة منقوش علیھا &quot;10TV &quot;من جھة واحدة و جلیة (غیر منقوشة) من الجھة الأخرى. □ أقراص تورڤاكول ۲۰ ھي أقراص ھي أقراص بیضاء إلى سكریة اللون مستدیرة مسطحة ثنائیة التحدب مغلفة منقوش علیھا &quot;20TV &quot;من جھة واحدة و جلیة (غیر منقوشة) من الجھة الأخرى. □ أقراص تورڤاكول ٤۰ ھي أقراص بیضاء إلى سكریة اللون مستطیلة مسطحة ثنائیة التحدب مغلفة منقوش علیھا &quot;40TV &quot; من جھة واحدة و جلیة (غیر منقوشة) من الجھة الأخرى. □ علب تحتوي على ۳۰ قرص من تورڤاكول ۱۰ محفوظة في أشرطة. □ علب تحتوي على ۱٤۸۰ قرص من تورڤاكول ۱۰ محفوظة في أشرطة. □ علب تحتوي على ۳۰ قرص من تورڤاكول ۲۰ محفوظة في أشرطة. □ علب تحتوي على ۳۰</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><br />الشركة الأردنیة لإنتاج الأدویة. ص.ب. ،۱٥۱ أم العمد -۱٦۱۹۷ الأردن. المملكة العربیة السعودیة: للإبلاغ عن الأعراض الجانبیة: المركز الوطني للتیقظ الدوائي: فاكس: ۹٦٦۱۱۲۰٥۷٦٦۲ ،+ مركز الاتصال بالھیئة العامة للغذاء و الدواء في السعودیة: ،۱۹۹۹۹ البرید الإلكتروني: Npc.drug@sfda.gov.sa الموقع الإلكتروني: https://ade.sfda.gov.sa</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ايلول 2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                TORVACOL 40 Tablet
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Active Ingredient:

Each film-coated tablet contains 40mg of Atorvastatin    as Atorvastatin   Calcium

Inactive Ingredients:

Inactive ingredients(s) and amount (s) per unit dose:
NAMES OF INGREDIENTS	QUANTITY 
(MG/TABLET)
Microcrystalline Cellulose 180 m	159.40
Calcium Carbonate 90% Granules	156.48
Lactose Monohydrate (Super -TAB Spray dried)	157.28
Hydroxypropyl Cellulose (klucel EF)	13.44
Croscarmellose Sodium	43.52
Magnesium Stearate 	5.92
Hydroxypropyl Methylcellulose Type 2910 (Methocel E5)	12.96
Titanium Dioxide 	5.68
Polyethylene Glycol 400 	1.36















      *For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                TORVACOL 40:

White to Off-white oblong shallow biconvex film coated tablet debossed with
 “TV 40” on one side and plain on the other side

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hypercholesterolaemia</u></p><p>TORVACOL is indicated as an adjunct to diet for reduction of elevated total cholesterol (total-C), LDL-cholesterol (LDL-C), apolipoprotein B, and triglycerides in adults, adolescents and children aged 10 years or older with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (Corresponding to Types IIa and IIb of the Fredrickson classification) when response to diet and other nonpharmacological measures is inadequate.</p><p>Liptor is also indicated to reduce total-C and LDL-C in adults with homozygous familial hypercholesterolaemia as an adjunct to other lipid-lowering treatments (e.g. LDL apheresis) or if such treatments are unavailable.</p><p><u>Prevention of cardiovascular disease</u></p><p>Prevention of cardiovascular events in adult patients estimated to have a high risk for a first cardiovascular event (see section 5.1), as an adjunct to correction of other risk factors.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong><u>Posology</u></p><p>The patient should be placed on a standard cholesterol-lowering diet before receiving TORVACOL and should continue on this diet during treatment with TORVACOL.</p><p>The dose should be individualised according to baseline LDL-C levels, the goal of therapy, and patient response.</p><p>The usual starting dose is 10 mg once a day. Adjustment of dose should be made at intervals of 4 weeks or more. The maximum dose is 80 mg once a day.</p><p><em>Primary hypercholesterolaemia and combined (mixed) hyperlipidaemia</em></p><p>The majority of patients are controlled with TORVACOL 10 mg once a day. A therapeutic response is evident within 2 weeks, and the maximum therapeutic response is usually achieved within 4 weeks. The response is maintained during chronic therapy.</p><p><em>Heterozygous familial hypercholesterolaemia</em></p><p>Patients should be started with TORVACOL 10 mg daily. Doses should be individualised and adjusted every 4 weeks to 40 mg daily. Thereafter, either the dose may be increased to a maximum of 80 mg daily or a bile acid sequestrant may be combined with 40 mg atorvastatin once daily.</p><p><em>Homozygous familial hypercholesterolaemia</em></p><p>Only limited data are available (see section 5.1).</p><p>The dose of atorvastatin in patients with homozygous familial hypercholesterolemia is 10 to 80 mg daily (see section 5.1). Atorvastatin should be used as an adjunct to other lipid-lowering treatments (e.g. LDL apheresis) in these patients or if such treatments are unavailable.</p><p>&nbsp;</p><p><em>Prevention of cardiovascular disease</em></p><p>In the primary prevention trials the dose was 10 mg/day. Higher doses may be necessary in order to attain (LDL-) cholesterol levels according to current guidelines.</p><p><em>Renal impairment</em></p><p>No adjustment of dose is required (see section 4.4).</p><p><em>Hepatic impairment</em></p><p>TORVACOL should be used with caution in patients with hepatic impairment (see sections 4.4 and 5.2). TORVACOL is contraindicated in patients with active liver disease (see section 4.3).</p><p><em>Co-administration with other medicines</em></p><p>In patients taking the hepatitis C antiviral agents elbasvir/grazoprevir or letermovir for cytomegalovirus infection prophylaxis concomitantly with atorvastatin, the dose of atorvastatin should not exceed 20 mg/day (see sections 4.4 and 4.5).</p><p>Use of atorvastatin is not recommended in patients taking letermovir co-administered with ciclosporin (see sections 4.4 and 4.5).</p><p><em>Elderly</em></p><p>Efficacy and safety in patients older than 70 using recommended doses are similar to those seen in the general population.</p><p><em>Paediatric population</em></p><p><em><u>Hypercholesterolaemia</u></em></p><p>Paediatric use should only be carried out by physicians experienced in the treatment of paediatric hyperlipidaemia and patients should be re-evaluated on a regular basis to assess progress.</p><p>For patients with Heterozygous Familial Hypercholesterolemia aged 10 years and above, the recommended starting dose of atorvastatin is 10 mg per day (see section 5.1). The dose may be increased to 80 mg daily, according to the response and tolerability. Doses should be individualised according to the recommended goal of therapy. Adjustments should be made at intervals of 4 weeks or more. The dose titration to 80 mg daily is supported by study data in adults and by limited clinical data from studies in children with Heterozygous Familial Hypercholesterolemia (see sections 4.8 and 5.1).</p><p>There are limited safety and efficacy data available in children with Heterozygous Familial Hypercholesterolemia between 6 to 10 years of age derived from open-label studies. Atorvastatin is not indicated in the treatment of patients below the age of 10 years. Currently available data are described in sections 4.8, 5.1 and 5.2 but no recommendation on a posology can be made.</p><p>Other pharmaceutical forms/strengths may be more appropriate for this population.</p><p><u>Method of administration</u></p><p>TORVACOL is for oral administration. Each daily dose of atorvastatin is given all at once and may be given at any time of day with or without food.</p><p>TORVACOL is contraindicated in patients:</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                TORVACOL is contraindicated in patients:
•	With hypersensitivity to the active substance or to any of the excipients listed in section 6.1
•	with active liver disease or unexplained persistent elevations of serum transaminases exceeding 3 times the upper limit of normal
•	while breast-feeding 
•	treated with the hepatitis C antivirals glecaprevir/pibrentasvir

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hepatic impairment </u></p><p>Liver function tests should be performed before the initiation of treatment and periodically thereafter. Patients who develop any signs or symptoms suggestive of liver injury should have liver function tests performed. Patients who develop increased transaminase levels should be monitored until the abnormality(ies) resolve. Should an increase in transaminases of greater than 3 times the upper limit of normal (ULN) persist, reduction of dose or withdrawal of TORVACOL is recommended (see section 4.8).</p><p>TORVACOL should be used with caution in patients who consume substantial quantities of alcohol and/or have a history of liver disease.</p><p><u>Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL)</u></p><p>In a post-hoc analysis of stroke subtypes in patients without coronary heart disease (CHD) who had a recent stroke or transient ischemic attack (TIA) there was a higher incidence of haemorrhagic stroke in patients initiated on atorvastatin 80 mg compared to placebo. The increased risk was particularly noted in patients with prior haemorrhagic stroke or lacunar infarct at study entry. For patients with prior haemorrhagic stroke or lacunar infarct, the balance of risks and benefits of atorvastatin 80 mg is uncertain, and the potential risk of haemorrhagic stroke should be carefully considered before initiating treatment (see section 5.1)<em>.</em></p><p><u>Skeletal muscle effects</u></p><p>Atorvastatin, like other HMG-CoA reductase inhibitors, may in rare occasions affect the skeletal muscle and cause myalgia, myositis, and myopathy that may progress to rhabdomyolysis, a potentially life-threatening condition characterised by markedly elevated creatine kinase (CK) levels (&gt; 10 times ULN), myoglobinaemia and myoglobinuria which may lead to renal failure.</p><p>There have been very rare reports of an immune mediated necrotizing myopathy (IMNM) during or after treatment with some statins. IMNM is clinically characterised by persistent proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment.</p><p><em>Before the treatment</em></p><p>Atorvastatin should be prescribed with caution in patients with pre-disposing factors for rhabdomyolysis. A CK level should be measured before starting statin treatment in the following situations:</p><p>- Renal impairment</p><p>- Hypothyroidism</p><p>- Personal or familial history of hereditary muscular disorders</p><p>- Previous history of muscular toxicity with a statin or fibrate</p><p>- Previous history of liver disease and/or where substantial quantities of alcohol are consumed</p><p>- In elderly (age &gt; 70 years), the necessity of such measurement should be considered, according to the presence of other predisposing factors for rhabdomyolysis</p><p>- Situations where an increase in plasma levels may occur, such as interactions (see section 4.5) and special populations including genetic subpopulations (see section 5.2)</p><p>In such situations, the risk of treatment should be considered in relation to possible benefit, and clinical monitoring is recommended.</p><p>If CK levels are significantly elevated (&gt; 5 times ULN) at baseline, treatment should not be started.</p><p><em>Creatine kinase measurement</em></p><p>Creatine kinase (CK) should not be measured following strenuous exercise or in the presence of any plausible alternative cause of CK increase as this makes value interpretation difficult. If CK levels are significantly elevated at baseline (&gt; 5 times ULN), levels should be remeasured within 5 to 7 days later to confirm the results.</p><p><em>Whilst on treatment</em></p><p>- Patients must be asked to promptly report muscle pain, cramps, or weakness especially if accompanied by malaise or fever.</p><p>- If such symptoms occur whilst a patient is receiving treatment with atorvastatin, their CK levels should be measured. If these levels are found to be significantly elevated (&gt; 5 times ULN), treatment should be stopped.</p><p>- If muscular symptoms are severe and cause daily discomfort, even if the CK levels are elevated to &le; 5 x ULN, treatment discontinuation should be considered.</p><p>- If symptoms resolve and CK levels return to normal, then re-introduction of atorvastatin or introduction of an alternative statin may be considered at the lowest dose and with close monitoring.</p><p>- Atorvastatin must be discontinued if clinically significant elevation of CK levels (&gt; 10 x ULN) occur, or if rhabdomyolysis is diagnosed or suspected.</p><p><u>Concomitant treatment with other medicinal products</u></p><p>Risk of rhabdomyolysis is increased when atorvastatin is administered concomitantly with certain medicinal products that may increase the plasma concentration of atorvastatin such as potent inhibitors of CYP3A4 or transport proteins (e.g. ciclosporin, telithromycin, clarithromycin, delavirdine, stiripentol, ketoconazole, voriconazole, itraconazole, posaconazole, letermovir and HIV protease inhibitors including ritonavir, lopinavir, atazanavir, indinavir, darunavir, tipranavir/ritonavir, etc). The risk of myopathy may also be increased with the concomitant use of gemfibrozil and other fibric acid derivates, antivirals for the treatment of hepatitis C (HCV) (boceprevir, telaprevir, elbasvir/grazoprevir), erythromycin, niacin or ezetimibe. If possible, alternative (non-interacting) therapies should be considered instead of these medicinal products.</p><p>In cases where co-administration of these medicinal products with atorvastatin is necessary, the benefit and the risk of concurrent treatment should be carefully considered. When patients are receiving medicinal products that increase the plasma concentration of atorvastatin, a lower maximum dose of atorvastatin is recommended. In addition, in the case of potent CYP3A4 inhibitors, a lower starting dose of atorvastatin should be considered and appropriate clinical monitoring of these patients is recommended (see section 4.5).</p><p>Atorvastatin must not be co-administered with systemic formulations of fusidic acid or within 7 days of stopping fusidic acid treatment. In patients where the use of systemic fusidic acid is considered essential, statin treatment should be discontinued throughout the duration of fusidic acid treatment. There have been reports of rhabdomyolysis (including some fatalities) in patients receiving fusidic acid and statins in combination (see section 4.5). The patient should be advised to seek medical advice immediately if they experience any symptoms of muscle weakness, pain or tenderness.</p><p>Statin therapy may be re-introduced seven days after the last dose of fusidic acid.</p><p>In exceptional circumstances, where prolonged systemic fusidic acid is needed, e.g., for the treatment of severe infections, the need for co-administration of TORVACOL and fusidic acid should only be considered on a case by case basis and under close medical supervision.</p><p><u>Paediatric population</u></p><p>No clinically significant effect on growth and sexual maturation was observed in a 3-year study based on the assessment of overall maturation and development, assessment of Tanner Stage, and measurement of height and weight (see section 4.8).</p><p><u>Interstitial lung disease</u></p><p>Exceptional cases of interstitial lung disease have been reported with some statins, especially with long term therapy (see section 4.8). Presenting features can include dyspnoea, non-productive cough and deterioration in general health (fatigue, weight loss and fever). If it is suspected a patient has developed interstitial lung disease, statin therapy should be discontinued.</p><p><u>Diabetes Mellitus</u></p><p>Some evidence suggests that statins as a class raise blood glucose and in some patients, at high risk of future diabetes, may produce a level of hyperglycaemia where formal diabetes care is appropriate. This risk, however, is outweighed by the reduction in vascular risk with statins and therefore should not be a reason for stopping statin treatment. Patients at risk (fasting glucose 5.6 to 6.9 mmol/L, BMI&gt;30kg/m<sup>2</sup>, raised triglycerides, hypertension) should be monitored both clinically and biochemically according to national guidelines.</p><p>Myasthenia gravis</p><p>In few cases, statins have been reported to induce de novo or aggravate pre-existing myasthenia gravis or ocular myasthenia (see section 4.8). {(Invented) name} should be discontinued in case of aggravation of symptoms. Recurrences when the same or a different statin was (re-) administered have been reported.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Excipients</u></p><p>Torvacol contains lactose. Patients with rare hereditary problems of galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption should not take this medicine</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Effect of co-administered medicinal products on atorvastatin</u></p><p>Atorvastatin is metabolised by cytochrome P450 3A4 (CYP3A4) and is a substrate of the hepatic transporters, organic anion-transporting polypeptide 1B1 (OATP1B1) and 1B3 (OATP1B3) transporter. Metabolites of atorvastatin are substrates of OATP1B1. Atorvastatin is also identified as a substrate of the multi-drug resistance protein 1 (MDR1) and breast cancer resistance protein (BCRP), which may limit the intestinal absorption and biliary clearance of atorvastatin (see section 5.2). Concomitant administration of medicinal products that are inhibitors of CYP3A4 or transport proteins may lead to increased plasma concentrations of atorvastatin and an increased risk of myopathy. The risk might also be increased at concomitant administration of atorvastatin with other medicinal products that have a potential to induce myopathy, such as fibric acid derivates and ezetimibe (see section 4.3 and 4.4).</p><p><em>CYP3A4 inhibitors</em></p><p>Potent CYP3A4 inhibitors have been shown to lead to markedly increased concentrations of atorvastatin (see Table 1 and specific information below). Co-administration of potent CYP3A4 inhibitors (e.g. ciclosporin, telithromycin, clarithromycin, delavirdine, stiripentol, ketoconazole, voriconazole, itraconazole, posaconazole, some antivirals used in the treatment of HCV (e.g., elbasvir/grazoprevir), and HIV protease inhibitors including ritonavir, lopinavir, atazanavir, indinavir, darunavir, etc.) should be avoided if possible. In cases where co-administration of these medicinal products with atorvastatin cannot be avoided lower starting and maximum doses of atorvastatin should be considered and appropriate clinical monitoring of the patient is recommended (see Table 1).</p><p>Moderate CYP3A4 inhibitors (e.g. erythromycin, diltiazem, verapamil and fluconazole) may increase plasma concentrations of atorvastatin (see Table 1). An increased risk of myopathy has been observed with the use of erythromycin in combination with statins. Interaction studies evaluating the effects of amiodarone or verapamil on atorvastatin have not been conducted. Both amiodarone and verapamil are known to inhibit CYP3A4 activity and co-administration with atorvastatin may result in increased exposure to atorvastatin. Therefore, a lower maximum dose of atorvastatin should be considered and appropriate clinical monitoring of the patient is recommended when concomitantly used with moderate CYP3A4 inhibitors. Appropriate clinical monitoring is recommended after initiation or following dose adjustments of the inhibitor.</p><p><em>CYP3A4 inducers</em></p><p>Concomitant administration of atorvastatin with inducers of cytochrome P450 3A (e.g. efavirenz, rifampin, St. John&#39;s Wort) can lead to variable reductions in plasma concentrations of atorvastatin. Due to the dual interaction mechanism of rifampin, (cytochrome P450 3A induction and inhibition of hepatocyte uptake transporter OATP1B1), simultaneous co-administration of atorvastatin with rifampin is recommended, as delayed administration of atorvastatin after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations. The effect of rifampin on atorvastatin concentrations in hepatocytes is, however, unknown and if concomitant administration cannot be avoided, patients should be carefully monitored for efficacy.</p><p><em>Transport inhibitors</em></p><p>Inhibitors of transport proteins (e.g. ciclosporin, letermovir) can increase the systemic exposure of atorvastatin (see Table 1). The effect of inhibition of hepatic uptake transporters on atorvastatin concentrations in hepatocytes is unknown. If concomitant administration cannot be avoided, a dose reduction and clinical monitoring for efficacy is recommended (see Table 1).</p><p>Use of atorvastatin is not recommended in patients taking letermovir co-administered with ciclosporin (see section 4.4).</p><p><em>Gemfibrozil / fibric acid derivatives</em></p><p>The use of fibrates alone is occasionally associated with muscle related events, including rhabdomyolysis. The risk of these events may be increased with the concomitant use of fibric acid derivatives and atorvastatin. If concomitant administration cannot be avoided, the lowest dose of atorvastatin to achieve the therapeutic objective should be used and the patients should be appropriately monitored (see section 4.4).</p><p><em>Ezetimibe</em></p><p>The use of ezetimibe alone is associated with muscle related events, including rhabdomyolysis. The risk of these events may therefore be increased with concomitant use of ezetimibe and atorvastatin. Appropriate clinical monitoring of these patients is recommended.</p><p><em>Colestipol</em></p><p>Plasma concentrations of atorvastatin and its active metabolites were lower (ratio of atorvastatin concentration: 0.74) when colestipol was co-administered with TORVACOL. However, lipid effects were greater when TORVACOL and colestipol were co-administered than when either medicinal product was given alone.</p><p><em>Fusidic acid</em></p><p>The risk of myopathy including rhabdomyolysis may be increased by the concomitant administration of systemic fusidic acid with statins. The mechanism of this interaction (whether it is pharmacodynamic or pharmacokinetic, or both) is yet unknown. There have been reports of rhabdomyolysis (including some fatalities) in patients receiving this combination.</p><p>If treatment with systemic fusidic acid is necessary, atorvastatin treatment should be discontinued throughout the duration of the fusidic acid treatment (see section 4.4).</p><p><em>Colchicine</em></p><p>Although interaction studies with atorvastatin and colchicine have not been conducted, cases of myopathy have been reported with atorvastatin co-administered with colchicine, and caution should be exercised when prescribing atorvastatin with colchicine.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Effect of atorvastatin on co-administered medicinal products</u></p><p><em>Digoxin</em></p><p>When multiple doses of digoxin and 10 mg atorvastatin were co-administered, steady-state digoxin concentrations increased slightly. Patients taking digoxin should be monitored appropriately.</p><p><em>Oral contraceptives</em></p><p>Co-administration of TORVACOL with an oral contraceptive produced increases in plasma concentrations of norethindrone and ethinyl oestradiol.</p><p><em>Warfarin</em></p><p>In a clinical study in patients receiving chronic warfarin therapy, co-administration of atorvastatin 80 mg daily with warfarin caused a small decrease of about 1.7 seconds in prothrombin time during the first 4 days of dosing which returned to normal within 15 days of atorvastatin treatment. Although only very rare cases of clinically significant anticoagulant interactions have been reported, prothrombin time should be determined before starting atorvastatin in patients taking coumarin anticoagulants and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs. Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants. If the dose of atorvastatin is changed or discontinued, the same procedure should be repeated. Atorvastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants.</p><p><u>Paediatric population</u></p><p>Drug-drug interaction studies have only been performed in adults. The extent of interactions in the paediatric population is not known. The above mentioned interactions for adults and the warnings in section 4.4 should be taken into account for the paediatric population.</p><p><u>Drug interactions</u></p><p><strong><u>Table 1: Effect of co-administered medicinal products on the pharmacokinetics of atorvastatin</u></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>Co-administered medicinal product and dosing regimen</p></td><td colspan="4" style="vertical-align:top"><p>Atorvastatin</p></td></tr><tr><td style="vertical-align:top"><p>Dose (mg)</p></td><td style="vertical-align:top"><p>Ratio of AUC<sup>&amp;</sup></p></td><td style="vertical-align:top"><p>Clinical Recommendation<sup>#</sup></p></td><td>&nbsp;</td></tr><tr><td><p>Glecaprevir 400 mg OD/ Pibrentasvir 120 mg OD, 7 days</p></td><td><p>10 mg OD for 7 days</p></td><td><p>8.3</p></td><td style="vertical-align:top"><p>Co-administration with products containing glecaprevir or pibrentasvir is contraindicated (see section 4.3).</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Tipranavir 500 mg BID/ Ritonavir 200 mg BID, 8 days (days 14 to 21)</p></td><td style="vertical-align:top"><p>40 mg on day 1, 10 mg on day 20</p></td><td style="vertical-align:top"><p>9.4</p></td><td rowspan="3" style="vertical-align:top"><p>In cases where co-administration with atorvastatin is necessary, do not exceed 10 mg atorvastatin daily. Clinical monitoring of these patients is recommended.</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Telaprevir 750 mg q8h, 10 days</p></td><td style="vertical-align:top"><p>20 mg, SD</p></td><td style="vertical-align:top"><p>7.9</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Ciclosporin 5.2 mg/kg/day, stable dose</p></td><td style="vertical-align:top"><p>10 mg OD for 28 days</p></td><td style="vertical-align:top"><p>8.7</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Lopinavir 400 mg BID/ Ritonavir 100 mg BID, 14 days</p></td><td style="vertical-align:top"><p>20 mg OD for 4 days</p></td><td style="vertical-align:top"><p>5.9</p></td><td rowspan="2" style="vertical-align:top"><p>In cases where co-administration with atorvastatin is necessary, lower maintenance doses of atorvastatin are recommended. At atorvastatin doses exceeding 20 mg, clinical monitoring of these patients is recommended<em>.</em></p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Clarithromycin 500 mg BID, 9 days</p></td><td style="vertical-align:top"><p>80 mg OD for 8 days</p></td><td style="vertical-align:top"><p>4.5</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Saquinavir 400 mg BID/ Ritonavir (300 mg BID from days 5-7, increased to 400 mg BID on day 8), days 4-18, 30 min after atorvastatin dosing</p></td><td style="vertical-align:top"><p>40 mg OD for 4 days</p></td><td style="vertical-align:top"><p>3.9</p></td><td rowspan="5" style="vertical-align:top"><p>In cases where co-administration with atorvastatin is necessary, lower maintenance doses of atorvastatin are recommended. At atorvastatin doses exceeding 40 mg, clinical monitoring of these patients is recommended<em>.</em></p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Darunavir 300 mg BID/ Ritonavir 100 mg BID, 9 days</p></td><td style="vertical-align:top"><p>10 mg OD for 4 days</p></td><td style="vertical-align:top"><p>3.4</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Itraconazole 200 mg OD, 4 days</p></td><td style="vertical-align:top"><p>40 mg SD</p></td><td style="vertical-align:top"><p>3.3</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Fosamprenavir 700 mg BID/ Ritonavir 100 mg BID, 14 days</p></td><td style="vertical-align:top"><p>10 mg OD for 4 days</p></td><td style="vertical-align:top"><p>2.5</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Fosamprenavir 1400 mg BID, 14 days</p></td><td style="vertical-align:top"><p>10 mg OD for 4 days</p></td><td style="vertical-align:top"><p>2.3</p></td><td>&nbsp;</td></tr><tr><td><p>Elbasvir 50 mg OD/ Grazoprevir 200 mg OD, 13 days</p></td><td><p>10 mg SD</p></td><td><p>1.95</p></td><td style="vertical-align:top"><p>The dose of atorvastatin should not exceed a daily dose of 20 mg during co-administration with products containing elbasvir or grazoprevir.</p></td><td>&nbsp;</td></tr><tr><td><p>Letermovir 480 mg OD, 10 days</p></td><td><p>20 mg SD</p></td><td><p>3.29</p></td><td style="vertical-align:top"><p>The dose of atorvastatin should not exceed a daily dose of 20 mg during co administration with products containing letermovir.</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Nelfinavir 1250 mg BID, 14 days</p></td><td style="vertical-align:top"><p>10 mg OD for 28 days</p></td><td style="vertical-align:top"><p>1.74</p></td><td style="vertical-align:top"><p>No specific recommendation.</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Grapefruit Juice, 240 mL OD *</p></td><td style="vertical-align:top"><p>40 mg, SD</p></td><td style="vertical-align:top"><p>1.37</p></td><td style="vertical-align:top"><p>Concomitant intake of large quantities of grapefruit juice and atorvastatin is not recommended.</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Diltiazem 240 mg OD, 28 days</p></td><td style="vertical-align:top"><p>40 mg, SD</p></td><td style="vertical-align:top"><p>1.51</p></td><td style="vertical-align:top"><p>After initiation or following dose adjustments of diltiazem, appropriate clinical monitoring of these patients is recommended.</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Erythromycin 500 mg QID, 7 days</p></td><td style="vertical-align:top"><p>10 mg, SD</p></td><td style="vertical-align:top"><p>1.33</p></td><td style="vertical-align:top"><p>Lower maximum dose and clinical monitoring of these patients is recommended.</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Amlodipine 10 mg, single dose</p></td><td style="vertical-align:top"><p>80 mg, SD</p></td><td style="vertical-align:top"><p>1.18</p></td><td style="vertical-align:top"><p>No specific recommendation.</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Cimetidine 300 mg QID, 2 weeks</p></td><td style="vertical-align:top"><p>10 mg OD for 2 weeks</p></td><td style="vertical-align:top"><p>1.00</p></td><td style="vertical-align:top"><p>No specific recommendation.</p></td><td>&nbsp;</td></tr><tr><td><p>Colestipol 10 g BID, 24 weeks</p></td><td><p>40 mg OD for 8 weeks</p></td><td><p>0.74**</p></td><td><p>No specific recommendation</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Antacid suspension of magnesium and aluminium hydroxides, 30 mL QID, 17 days</p></td><td style="vertical-align:top"><p>10 mg OD for 15 days</p></td><td style="vertical-align:top"><p>0.66</p></td><td style="vertical-align:top"><p>No specific recommendation.</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Efavirenz 600 mg OD, 14 days</p></td><td style="vertical-align:top"><p>10 mg for 3 days</p></td><td style="vertical-align:top"><p>0.59</p></td><td style="vertical-align:top"><p>No specific recommendation.</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Rifampin 600 mg OD, 7 days (co-administered)</p></td><td style="vertical-align:top"><p>40 mg SD</p></td><td style="vertical-align:top"><p>1.12</p></td><td rowspan="2" style="vertical-align:top"><p>If co-administration cannot be avoided, simultaneous co-administration of atorvastatin with rifampin is recommended, with clinical monitoring.</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Rifampin 600 mg OD, 5 days (doses separated)</p></td><td style="vertical-align:top"><p>40 mg SD</p></td><td style="vertical-align:top"><p>0.20</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Gemfibrozil 600 mg BID, 7 days</p></td><td style="vertical-align:top"><p>40 mg SD</p></td><td style="vertical-align:top"><p>1.35</p></td><td style="vertical-align:top"><p>Lower starting dose and clinical monitoring of these patients is recommended.</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Fenofibrate 160 mg OD, 7 days</p></td><td style="vertical-align:top"><p>40 mg SD</p></td><td style="vertical-align:top"><p>1.03</p></td><td style="vertical-align:top"><p>Lower starting dose and clinical monitoring of these patients is recommended.</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Boceprevir 800 mg TID, 7 days</p></td><td style="vertical-align:top"><p>40 mg SD</p></td><td style="vertical-align:top"><p>2.3</p></td><td style="vertical-align:top"><p>Lower starting dose and clinical monitoring of these patients is recommended. The dose of atorvastatin should not exceed a daily dose of 20 mg during co-administration with boceprevir.</p></td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p><sup>&amp;</sup>&nbsp;Represents ratio of treatments (co-administered drug plus atorvastatin versus atorvastatin alone).</p><p><sup>#</sup>&nbsp;See sections 4.4 and 4.5 for clinical significance.</p><p>* Contains one or more components that inhibit CYP3A4 and can increase plasma concentrations of medicinal products metabolised by CYP3A4. Intake of one 240 ml glass of grapefruit juice also resulted in a decreased AUC of 20.4% for the active orthohydroxy metabolite. Large quantities of grapefruit juice (over 1.2 l daily for 5 days) increased AUC of atorvastatin 2.5 fold and AUC of active (atorvastatin and metabolites) HMG-CoA reductase inhibitors 1.3 fold.</p><p>** Ratio based on a single sample taken 8-16 h post dose.</p><p>OD = once daily; SD = single dose; BID = twice daily; TID = three times daily; QID = four times daily.</p><p><strong><u>Table 2: Effect of atorvastatin on the pharmacokinetics of co-administered medicinal products</u></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>Atorvastatin and dosing regimen</p></td><td colspan="3" style="vertical-align:top"><p>Co-administered medicinal product</p></td></tr><tr><td style="vertical-align:top"><p>Medicinal product/Dose (mg)</p></td><td style="vertical-align:top"><p>Ratio of AUC<sup>&amp;</sup></p></td><td style="vertical-align:top"><p>Clinical Recommendation</p></td></tr><tr><td style="vertical-align:top"><p>80 mg OD for 10 days</p></td><td style="vertical-align:top"><p>Digoxin 0.25 mg OD, 20 days</p></td><td style="vertical-align:top"><p>1.15</p></td><td style="vertical-align:top"><p>Patients taking digoxin should be monitored appropriately.</p></td></tr><tr><td style="vertical-align:top"><p>40 mg OD for 22 days</p></td><td style="vertical-align:top"><p>Oral contraceptive OD, 2 months</p><p>- norethindrone 1 mg</p><p>-ethinyl estradiol 35 &micro;g</p></td><td style="vertical-align:top"><p>1.28</p><p>1.19</p></td><td style="vertical-align:top"><p>No specific recommendation.</p></td></tr><tr><td style="vertical-align:top"><p>80 mg OD for 15 days</p></td><td style="vertical-align:top"><p>* Phenazone, 600 mg SD</p></td><td style="vertical-align:top"><p>1.03</p></td><td style="vertical-align:top"><p>No specific recommendation.</p></td></tr><tr><td style="vertical-align:top"><p>10 mg, SD</p></td><td style="vertical-align:top"><p>Tipranavir 500 mg BID/ritonavir 200 mg BID, 7 days</p></td><td style="vertical-align:top"><p>1.08</p></td><td style="vertical-align:top"><p>No specific recommendation.</p></td></tr><tr><td style="vertical-align:top"><p>10 mg, OD for 4 days</p></td><td style="vertical-align:top"><p>Fosamprenavir 1400 mg BID, 14 days</p></td><td style="vertical-align:top"><p>0.73</p></td><td style="vertical-align:top"><p>No specific recommendation.</p></td></tr><tr><td style="vertical-align:top"><p>10 mg OD for 4 days</p></td><td style="vertical-align:top"><p>Fosamprenavir 700 mg BID/ritonavir 100 mg BID, 14 days</p></td><td style="vertical-align:top"><p>0.99</p></td><td style="vertical-align:top"><p>No specific recommendation.</p></td></tr></tbody></table><p><sup>&amp;&nbsp;</sup>Represents ratio of treatments (co-administered drug plus atorvastatin versus atorvastatin alone).</p><p>* Co-administration of multiple doses of atorvastatin and phenazone showed little or no detectable effect in the clearance of phenazone.</p><p>OD = once daily; SD = single dose; BID = twice daily.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential</u></p><p>Women of child-bearing potential should use appropriate contraceptive measures during treatment (see section 4.3).</p><p><u>Pregnancy</u></p><p>Safety in pregnant women has not been established. No controlled clinical trials with atorvastatin have been conducted in pregnant women. Rare reports of congenital anomalies following intrauterine exposure to HMG-CoA reductase inhibitors have been received. Studies in animals have shown toxicity to reproduction (see section 5.3).</p><p>Maternal treatment with atorvastatin may reduce the fetal levels of mevalonate which is a precursor of cholesterol biosynthesis. Atherosclerosis is a chronic process, and ordinarily discontinuation of lipid-lowering medicinal products during pregnancy should have little impact on the long-term risk associated with primary hypercholesterolaemia.</p><p>Multiple larger, well-designed, and controlled observational studies did not find an increase in major birth defects associated with use of statins during pregnancy.</p><p><u>Breast-feeding</u></p><p>It is unknown whether atorvastatin or its metabolites are excreted in human milk. In rats, plasma concentrations of atorvastatin and its active metabolites are similar to those in milk (see section 5.3). Because of the potential for serious adverse reactions, women taking TORVACOL should not breast-feed their infants (see section 4.3). Atorvastatin is contraindicated during breast-feeding (see section 4.3).</p><p><u>Fertility</u></p><p>In animal studies atorvastatin had no effect on male or female fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Torvacol has negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the atorvastatin placebo-controlled clinical trial database of 16,066 (8755 TORVACOL vs. 7311 placebo) patients treated for a mean period of 53 weeks, 5.2% of patients on atorvastatin discontinued due to adverse reactions compared to 4.0% of the patients on placebo.</p><p>Based on data from clinical studies and extensive post-marketing experience, the following table presents the adverse reaction profile for TORVACOL.</p><p>Estimated frequencies of reactions are ranked according to the following convention: common (&ge; 1/100, &lt; 1/10); uncommon (&ge; 1/1,000, &lt; 1/100); rare (&ge; 1/10,000, &lt; 1/1,000); very rare (&lt; 1/10,000), not known (cannot be estimated from the available data).</p><p><u>Infections and infestations</u></p><p>Common: nasopharyngitis.</p><p><u>Blood and lymphatic system disorders</u></p><p>Rare: thrombocytopenia.</p><p><u>Immune system disorders</u></p><p>Common: allergic reactions.</p><p>Very rare: anaphylaxis.</p><p><u>Metabolism and nutrition disorders</u></p><p>Common: hyperglycaemia.</p><p>Uncommon: hypoglycaemia, weight gain, anorexia.</p><p><u>Psychiatric disorders</u></p><p>Uncommon: nightmare, insomnia.</p><p><u>Nervous system disorders</u></p><p>Common: headache.</p><p>Uncommon: dizziness, paraesthesia, hypoesthesia, dysgeusia, amnesia.</p><p>Rare: peripheral neuropathy.</p><p>Not Known: myasthenia gravis.</p><p><u>Eye disorders</u></p><p>Uncommon: vision blurred.</p><p>Rare: visual disturbance.</p><p>Not Known: ocular myasthenia.</p><p><u>Ear and labyrinth disorders</u></p><p>Uncommon: tinnitus.</p><p>Very rare: hearing loss.</p><p><u>Respiratory, thoracic and mediastinal disorders</u></p><p>Common: pharyngolaryngeal pain, epistaxis.</p><p><u>Gastrointestinal disorders</u></p><p>Common: constipation, flatulence, dyspepsia, nausea, diarrhoea.</p><p>Uncommon: vomiting, abdominal pain upper and lower, eructation, pancreatitis.</p><p><u>Hepatobiliary disorders</u></p><p>Uncommon: hepatitis.</p><p>Rare: cholestasis.</p><p>Very rare: hepatic failure.</p><p><u>Skin and subcutaneous tissue disorders</u></p><p>Uncommon: urticaria, skin rash, pruritus, alopecia.</p><p>Rare: angioneurotic oedema, dermatitis bullous including erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis.</p><p><u>Musculoskeletal and connective tissue disorders</u></p><p>Common: myalgia, arthralgia, pain in extremity, muscle spasms, joint swelling, back pain.</p><p>Uncommon: neck pain, muscle fatigue.</p><p>Rare: myopathy, myositis, rhabdomyolysis, muscle rupture, tendonopathy, sometimes complicated by rupture.</p><p>Very rare: lupus-like syndrome.</p><p>Not known: immune mediated necrotizing myopathy (see section 4.4).</p><p><u>Reproductive system and breast disorders</u></p><p>Very rare: gynecomastia.</p><p><u>General disorders and administration site conditions</u></p><p>Uncommon: malaise, asthenia, chest pain, peripheral oedema, fatigue, pyrexia.</p><p><u>Investigations</u></p><p>Common: liver function test abnormal, blood creatine kinase increased.</p><p>Uncommon: white blood cells urine positive.</p><p>As with other HMG-CoA reductase inhibitors elevated serum transaminases have been reported in patients receiving TORVACOL. These changes were usually mild, transient, and did not require interruption of treatment. Clinically important (&gt; 3 times upper normal limit) elevations in serum transaminases occurred in 0.8% patients on TORVACOL. These elevations were dose related and were reversible in all patients.</p><p>Elevated serum creatine kinase (CK) levels greater than 3 times upper limit of normal occurred in 2.5% of patients on TORVACOL, similar to other HMG-CoA reductase inhibitors in clinical trials. Levels above 10 times the normal upper range occurred in 0.4% TORVACOL-treated patients (see section 4.4).</p><p><u>Paediatric population</u></p><p>Paediatric patients aged from 10 to 17 years of age treated with atorvastatin had an adverse experience profile generally similar to that of patients treated with placebo, the most common adverse experiences observed in both groups, regardless of causality assessment, were infections. No clinically significant effect on growth and sexual maturation was observed in a 3-year study based on the assessment of overall maturation and development, assessment of Tanner Stage, and measurement of height and weight. The safety and tolerability profile in paediatric patients was similar to the known safety profile of atorvastatin in adult patients.</p><p>The clinical safety database includes safety data for 520 paediatric patients who received atorvastatin, among which 7 patients were &lt; 6 years old, 121 patients were in the age range of 6 to 9, and 392 patients were in the age range of 10 to 17. Based on the data available, the frequency, type and severity of adverse reactions in children is similar to adults.</p><p><u>The following adverse events have been reported with some statins:</u></p><p>&bull; Sexual dysfunction.</p><p>&bull; Depression.</p><p>&bull; Exceptional cases of interstitial lung disease, especially with long term therapy (see section 4.4).</p><p>&bull; Diabetes Mellitus: Frequency will depend on the presence or absence of risk factors (fasting blood glucose &ge; 5.6 mmol/L, BMI&gt;30kg/m<sup>2</sup>, raised triglycerides, history of hypertension).</p><p>Saudi Arabia: To report any side effect(s): National Pharmacovigilance Center (NPC):&nbsp; Fax: +966-11-205-7662, SFDA Call center: 19999, E-mail: npc.drug@sfda.gov.sa, Website: https://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the atorvastatin placebo-controlled clinical trial database of 16,066 (8755 TORVACOL vs. 7311 placebo) patients treated for a mean period of 53 weeks, 5.2% of patients on atorvastatin discontinued due to adverse reactions compared to 4.0% of the patients on placebo.</p><p>Based on data from clinical studies and extensive post-marketing experience, the following table presents the adverse reaction profile for TORVACOL.</p><p>Estimated frequencies of reactions are ranked according to the following convention: common (&ge; 1/100, &lt; 1/10); uncommon (&ge; 1/1,000, &lt; 1/100); rare (&ge; 1/10,000, &lt; 1/1,000); very rare (&lt; 1/10,000), not known (cannot be estimated from the available data).</p><p><u>Infections and infestations</u></p><p>Common: nasopharyngitis.</p><p><u>Blood and lymphatic system disorders</u></p><p>Rare: thrombocytopenia.</p><p><u>Immune system disorders</u></p><p>Common: allergic reactions.</p><p>Very rare: anaphylaxis.</p><p><u>Metabolism and nutrition disorders</u></p><p>Common: hyperglycaemia.</p><p>Uncommon: hypoglycaemia, weight gain, anorexia.</p><p><u>Psychiatric disorders</u></p><p>Uncommon: nightmare, insomnia.</p><p><u>Nervous system disorders</u></p><p>Common: headache.</p><p>Uncommon: dizziness, paraesthesia, hypoesthesia, dysgeusia, amnesia.</p><p>Rare: peripheral neuropathy.</p><p>Not Known: myasthenia gravis.</p><p><u>Eye disorders</u></p><p>Uncommon: vision blurred.</p><p>Rare: visual disturbance.</p><p>Not Known: ocular myasthenia.</p><p><u>Ear and labyrinth disorders</u></p><p>Uncommon: tinnitus.</p><p>Very rare: hearing loss.</p><p><u>Respiratory, thoracic and mediastinal disorders</u></p><p>Common: pharyngolaryngeal pain, epistaxis.</p><p><u>Gastrointestinal disorders</u></p><p>Common: constipation, flatulence, dyspepsia, nausea, diarrhoea.</p><p>Uncommon: vomiting, abdominal pain upper and lower, eructation, pancreatitis.</p><p><u>Hepatobiliary disorders</u></p><p>Uncommon: hepatitis.</p><p>Rare: cholestasis.</p><p>Very rare: hepatic failure.</p><p><u>Skin and subcutaneous tissue disorders</u></p><p>Uncommon: urticaria, skin rash, pruritus, alopecia.</p><p>Rare: angioneurotic oedema, dermatitis bullous including erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis.</p><p><u>Musculoskeletal and connective tissue disorders</u></p><p>Common: myalgia, arthralgia, pain in extremity, muscle spasms, joint swelling, back pain.</p><p>Uncommon: neck pain, muscle fatigue.</p><p>Rare: myopathy, myositis, rhabdomyolysis, muscle rupture, tendonopathy, sometimes complicated by rupture.</p><p>Very rare: lupus-like syndrome.</p><p>Not known: immune mediated necrotizing myopathy (see section 4.4).</p><p><u>Reproductive system and breast disorders</u></p><p>Very rare: gynecomastia.</p><p><u>General disorders and administration site conditions</u></p><p>Uncommon: malaise, asthenia, chest pain, peripheral oedema, fatigue, pyrexia.</p><p><u>Investigations</u></p><p>Common: liver function test abnormal, blood creatine kinase increased.</p><p>Uncommon: white blood cells urine positive.</p><p>As with other HMG-CoA reductase inhibitors elevated serum transaminases have been reported in patients receiving TORVACOL. These changes were usually mild, transient, and did not require interruption of treatment. Clinically important (&gt; 3 times upper normal limit) elevations in serum transaminases occurred in 0.8% patients on TORVACOL. These elevations were dose related and were reversible in all patients.</p><p>Elevated serum creatine kinase (CK) levels greater than 3 times upper limit of normal occurred in 2.5% of patients on TORVACOL, similar to other HMG-CoA reductase inhibitors in clinical trials. Levels above 10 times the normal upper range occurred in 0.4% TORVACOL-treated patients (see section 4.4).</p><p><u>Paediatric population</u></p><p>Paediatric patients aged from 10 to 17 years of age treated with atorvastatin had an adverse experience profile generally similar to that of patients treated with placebo, the most common adverse experiences observed in both groups, regardless of causality assessment, were infections. No clinically significant effect on growth and sexual maturation was observed in a 3-year study based on the assessment of overall maturation and development, assessment of Tanner Stage, and measurement of height and weight. The safety and tolerability profile in paediatric patients was similar to the known safety profile of atorvastatin in adult patients.</p><p>The clinical safety database includes safety data for 520 paediatric patients who received atorvastatin, among which 7 patients were &lt; 6 years old, 121 patients were in the age range of 6 to 9, and 392 patients were in the age range of 10 to 17. Based on the data available, the frequency, type and severity of adverse reactions in children is similar to adults.</p><p><u>The following adverse events have been reported with some statins:</u></p><p>&bull; Sexual dysfunction.</p><p>&bull; Depression.</p><p>&bull; Exceptional cases of interstitial lung disease, especially with long term therapy (see section 4.4).</p><p>&bull; Diabetes Mellitus: Frequency will depend on the presence or absence of risk factors (fasting blood glucose &ge; 5.6 mmol/L, BMI&gt;30kg/m<sup>2</sup>, raised triglycerides, history of hypertension).</p><p>Saudi Arabia: To report any side effect(s): National Pharmacovigilance Center (NPC):&nbsp; Fax: +966-11-205-7662, SFDA Call center: 19999, E-mail: npc.drug@sfda.gov.sa, Website: https://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Lipid modifying agents, HMG-CoA-reductase inhibitors, ATC code: C10AA05</p><p>Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme responsible for the conversion of 3-hydroxy-3-methyl-glutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol. Triglycerides and cholesterol in the liver are incorporated into very low-density lipoproteins (VLDL) and released into the plasma for delivery to peripheral tissues. Low-density lipoprotein (LDL) is formed from VLDL and is catabolised primarily through the receptor with high affinity to LDL (LDL receptor).</p><p>Atorvastatin lowers plasma cholesterol and lipoprotein serum concentrations by inhibiting HMG-CoA reductase and subsequently cholesterol biosynthesis in the liver and increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL.</p><p>Atorvastatin reduces LDL production and the number of LDL particles. Atorvastatin produces a profound and sustained increase in LDL receptor activity coupled with a beneficial change in the quality of circulating LDL particles. Atorvastatin is effective in reducing LDL-C in patients with homozygous familial hypercholesterolaemia, a population that has not usually responded to lipid-lowering medicinal products.</p><p>Atorvastatin has been shown to reduce concentrations of total-C (30% - 46%), LDL-C (41% - 61%), apolipoprotein B (34% - 50%), and triglycerides (14% - 33%) while producing variable increases in HDL-C and apolipoprotein A1 in a dose response study. These results are consistent in patients with heterozygous familial hypercholesterolaemia, nonfamilial forms of hypercholesterolaemia, and mixed hyperlipidaemia, including patients with noninsulin-dependent diabetes mellitus.</p><p>Reductions in total-C, LDL-C, and apolipoprotein B have been proven to reduce risk for cardiovascular events and cardiovascular mortality.</p><p><u>Homozygous familial hypercholesterolaemia</u></p><p>In a multicentre 8 week open-label compassionate-use study with an optional extension phase of variable length, 335 patients were enrolled, 89 of which were identified as homozygous familial hypercholesterolaemia patients. From these 89 patients, the mean percent reduction in LDL-C was approximately 20%. Atorvastatin was administered at doses up to 80 mg/day.</p><p><u>Atherosclerosis</u></p><p>In the Reversing Atherosclerosis with Aggressive Lipid- Lowering Study (REVERSAL), the effect of intensive lipid lowering with atorvastatin 80 mg and standard degree of lipid lowering with pravastatin 40 mg on coronary atherosclerosis was assessed by intravascular ultrasound (IVUS), during angiography, in patients with coronary heart disease. In this randomised, double- blind, multicentre, controlled clinical trial, IVUS was performed at baseline and at 18 months in 502 patients. In the atorvastatin group (n=253), there was no progression of atherosclerosis.</p><p>The median percent change, from baseline, in total atheroma volume (the primary study criteria) was -0.4% (p=0.98) in the atorvastatin group and +2.7% (p=0.001) in the pravastatin group (n=249). When compared to pravastatin the effects of atorvastatin were statistically significant (p=0.02). The effect of intensive lipid lowering on cardiovascular endpoints (e. g. need for revascularisation, non fatal myocardial infarction, coronary death) was not investigated in this study.</p><p>In the atorvastatin group, LDL-C was reduced to a mean of 2.04 mmol/L &plusmn; 0.8 (78.9 mg/dl &plusmn; 30) from baseline 3.89 mmol/L &plusmn; 0.7 (150 mg/dl &plusmn; 28) and in the pravastatin group, LDL-C was reduced to a mean of 2.85 mmol/L &plusmn; 0.7 (110 mg/dl &plusmn; 26) from baseline 3.89 mmol/L &plusmn; 0.7 (150 mg/dl &plusmn; 26) (p&lt;0.0001). Atorvastatin also significantly reduced mean TC by 34.1% (pravastatin: -18.4%, p&lt;0.0001), mean TG levels by 20% (pravastatin: -6.8%, p&lt;0.0009), and mean apolipoprotein B by 39.1% (pravastatin: -22.0%, p&lt;0.0001). Atorvastatin increased mean HDL-C by 2.9% (pravastatin: +5.6%, p=NS). There was a 36.4% mean reduction in CRP in the atorvastatin group compared to a 5.2% reduction in the pravastatin group (p&lt;0.0001).</p><p>Study results were obtained with the 80 mg dose strength. Therefore, they cannot be extrapolated to the lower dose strengths.</p><p>The safety and tolerability profiles of the two treatment groups were comparable.</p><p>The effect of intensive lipid lowering on major cardiovascular endpoints was not investigated in this study. Therefore, the clinical significance of these imaging results with regard to the primary and secondary prevention of cardiovascular events is unknown.</p><p><u>Acute coronary syndrome</u></p><p>In the MIRACL study, atorvastatin 80 mg has been evaluated in 3,086 patients (atorvastatin n=1,538; placebo n=1,548) with an acute coronary syndrome (non Q-wave MI or unstable angina). Treatment was initiated during the acute phase after hospital admission and lasted for a period of 16 weeks. Treatment with atorvastatin 80 mg/day increased the time to occurrence of the combined primary endpoint, defined as death from any cause, nonfatal MI, resuscitated cardiac arrest, or angina pectoris with evidence of myocardial ischaemia requiring hospitalization, indicating a risk reduction by 16% (p=0.048). This was mainly due to a 26% reduction in re-hospitalisation for angina pectoris with evidence of myocardial ischaemia (p=0.018). The other secondary endpoints did not reach statistical significance on their own (overall: Placebo: 22.2%, Atorvastatin: 22.4%).</p><p>The safety profile of atorvastatin in the MIRACL study was consistent with what is described in section 4.8.</p><p><u>Prevention of cardiovascular disease</u></p><p>The effect of atorvastatin on fatal and non-fatal coronary heart disease was assessed in a randomised, double-blind, placebo-controlled study, the Anglo-Scandinavian Cardiac Outcomes Trial Lipid Lowering Arm (ASCOT-LLA). Patients were hypertensive, 40-79 years of age, with no previous myocardial infarction or treatment for angina, and with TC levels &le;6.5 mmol/L (251 mg/dl). All patients had at least 3 of the pre-defined cardiovascular risk factors: male gender, age &ge;55 years, smoking, diabetes, history of CHD in a first-degree relative, TC:HDL-C &gt;6, peripheral vascular disease, left ventricular hypertrophy, prior cerebrovascular event, specific ECG abnormality, proteinuria/albuminuria. Not all included patients were estimated to have a high risk for a first cardiovascular event.</p><p>Patients were treated with anti-hypertensive therapy (either amlodipine or atenolol-based regimen) and either atorvastatin 10 mg daily (n=5,168) or placebo (n=5,137).</p><p>The absolute and relative risk reduction effect of atorvastatin was as follows:</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:bottom"><p>Event</p></td><td style="vertical-align:top"><p>Relative Risk Reduction (%)</p></td><td style="vertical-align:top"><p>No. of Events (Atorvastatin vs Placebo)</p></td><td style="vertical-align:top"><p>Absolute Risk Reduction<sup>1</sup>&nbsp;(%)</p></td><td style="vertical-align:bottom"><p>p-value</p></td></tr><tr><td style="vertical-align:top"><p>Fatal CHD plus non-fatal MI</p><p>Total cardiovascular events and revascularization procedures</p><p>Total coronary events</p></td><td style="vertical-align:top"><p>36%</p><p>20%<br />&nbsp;</p><p>29%</p></td><td style="vertical-align:top"><p>100 vs. 154</p><p>389 vs. 483<br />&nbsp;</p><p>178 vs 247</p></td><td style="vertical-align:top"><p>1.1%</p><p>1.9%<br />&nbsp;</p><p>1.4%</p></td><td style="vertical-align:top"><p>0.0005</p><p>0.0008<br />&nbsp;</p><p>0.0006</p></td></tr></tbody></table><p><sup>1</sup>Based on difference in crude events rates occurring over a median follow-up of 3.3 years.</p><p>CHD = coronary heart disease; MI = myocardial infarction.</p><p>Total mortality and cardiovascular mortality were not significantly reduced (185 vs. 212 events, p=0.17 and 74 vs. 82 events, p=0.51). In the subgroup analyses by gender (81% males, 19% females), a beneficial effect of atorvastatin was seen in males but could not be established in females possibly due to the low event rate in the female subgroup. Overall and cardiovascular mortality were numerically higher in the female patients (38 vs. 30 and 17 vs. 12), but this was not statistically significant. There was significant treatment interaction by antihypertensive baseline therapy. The primary endpoint (fatal CHD plus non-fatal MI) was significantly reduced by atorvastatin in patients treated with amlodipine (HR 0.47 (0.32-0.69), p=0.00008), but not in those treated with atenolol (HR 0.83 (0.59-1.17), p=0.287).</p><p>The effect of atorvastatin on fatal and non-fatal cardiovascular disease was also assessed in a randomised, double-blind, multicentre, placebo-controlled trial, the Collaborative Atorvastatin Diabetes Study (CARDS) in patients with type 2 diabetes, 40-75 years of age, without prior history of cardiovascular disease, and with LDL-C &le;4.14 mmol/L (160 mg/dl) and TG &le;6.78 mmol/L (600 mg/dl). All patients had at least 1 of the following risk factors: hypertension, current smoking, retinopathy, microalbuminuria or macroalbuminuria.</p><p>Patients were treated with either atorvastatin 10 mg daily (n=1,428) or placebo (n=1,410) for a median follow-up of 3.9 years.</p><p>The absolute and relative risk reduction effect of atorvastatin was as follows:</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:bottom"><p>Event</p></td><td style="vertical-align:top"><p>Relative Risk Reduction (%)</p></td><td style="vertical-align:top"><p>No. of Events (Atorvastatin vs Placebo)</p></td><td style="vertical-align:top"><p>Absolute Risk Reduction<sup>1</sup>&nbsp;(%)</p></td><td style="vertical-align:bottom"><p>p-value</p></td></tr><tr><td style="vertical-align:top"><p>Major cardiovascular events (fatal and non-fatal AMI, silent MI, acute CHD death, unstable angina, CABG, PTCA, revascularization, stroke)</p><p>MI (fatal and non-fatal AMI, silent MI)</p><p>Strokes (Fatal and non-fatal)</p></td><td style="vertical-align:top"><p>37%</p><p>42%</p><p>48%</p></td><td style="vertical-align:top"><p>83 vs. 127</p><p>38 vs 64</p><p>21 vs. 39</p></td><td style="vertical-align:top"><p>3.2%</p><p>1.9%</p><p>1.3%</p></td><td style="vertical-align:top"><p>0.0010</p><p>0.0070</p><p>0.0163</p></td></tr></tbody></table><p><sup>1</sup>Based on difference in crude events rates occurring over a median follow-up of 3.9 years.</p><p>AMI = acute myocardial infarction; CABG = coronary artery bypass graft; CHD = coronary heart disease; MI = myocardial infarction; PTCA = percutaneous transluminal coronary angioplasty.</p><p>There was no evidence of a difference in the treatment effect by patient&#39;s gender, age, or baseline LDL-C level. A favourable trend was observed regarding the mortality rate (82 deaths in the placebo group vs. 61 deaths in the atorvastatin group, p=0.0592).</p><p><u>Recurrent stroke</u></p><p>In the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study, the effect of atorvastatin 80 mg daily or placebo on stroke was evaluated in 4731 patients who had a stroke or transient ischemic attack (TIA) within the preceding 6 months and no history of coronary heart disease (CHD). Patients were 60% male, 21-92 years of age (average age 63 years), and had an average baseline LDL of 133 mg/dL (3.4 mmol/L). The mean LDL-C was 73 mg/dL (1.9 mmol/L) during treatment with atorvastatin and 129 mg/dL (3.3 mmol/L) during treatment with placebo. Median follow-up was 4.9 years.</p><p>Atorvastatin 80 mg reduced the risk of the primary endpoint of fatal or non-fatal stroke by 15% (HR 0.85; 95% CI, 0.72-1.00; p=0.05 or 0.84; 95% CI, 0.71-0.99; p=0.03 after adjustment for baseline factors) compared to placebo. All cause mortality was 9.1% (216/2365) for atorvastatin versus 8.9% (211/2366) for placebo.</p><p>In a post-hoc analysis, atorvastatin 80 mg reduced the incidence of ischemic stroke (218/2365, 9.2% vs. 274/2366, 11.6%, p=0.01) and increased the incidence of haemorrhagic stroke (55/2365, 2.3% vs. 33/2366, 1.4%, p=0.02) compared to placebo.</p><p>&bull; The risk of haemorrhagic stroke was increased in patients who entered the study with prior haemorrhagic stroke (7/45 for atorvastatin versus 2/48 for placebo; HR 4.06; 95% CI, 0.84-19.57), and the risk of ischemic stroke was similar between groups (3/45 for atorvastatin versus 2/48 for placebo; HR 1.64; 95% CI, 0.27-9.82).</p><p>&bull; The risk of haemorrhagic stroke was increased in patients who entered the study with prior lacunar infarct (20/708 for atorvastatin versus 4/701 for placebo; HR 4.99; 95% CI, 1.71-14.61), but the risk of ischemic stroke was also decreased in these patients (79/708 for atorvastatin versus 102/701 for placebo; HR 0.76; 95% CI, 0.57-1.02). It is possible that the net risk of stroke is increased in patients with prior lacunar infarct who receive atorvastatin 80 mg/day.</p><p>All cause mortality was 15.6% (7/45) for atorvastatin versus 10.4% (5/48) in the subgroup of patients with prior haemorrhagic stroke. All cause mortality was 10.9% (77/708) for atorvastatin versus 9.1% (64/701) for placebo in the subgroup of patients with prior lacunar infarct.</p><p><u>Paediatric population</u></p><p><em>Heterozygous Familial Hypercholesterolaemia in Paediatric Patients aged 6-17 years old</em></p><p>An 8-week, open-label study to evaluate pharmacokinetics, pharmacodynamics, and safety and tolerability of atorvastatin was conducted in children and adolescents with genetically confirmed heterozygous familial hypercholesterolemia and baseline LDL-C &ge; 4 mmol/L. A total of 39 children and adolescents, 6 to 17 years of age, were enrolled. Cohort A included 15 children, 6 to 12 years of age and at Tanner Stage 1. Cohort B included 24 children, 10 to 17 years of age and at Tanner Stage &ge; 2.</p><p>The initial dose of atorvastatin was 5 mg daily of a chewable tablet in Cohort A and 10 mg daily of a tablet formulation in Cohort B. The atorvastatin dose was permitted to be doubled if a subject had not attained target LDL-C of &lt; 3.35 mmol/L at Week 4 and if atorvastatin was well tolerated.</p><p>Mean values for LDL-C, TC, VLDL-C, and Apo B decreased by Week 2 among all subjects. For subjects whose dose was doubled, additional decreases were observed as early as 2 weeks, at the first assessment, after dose escalation. The mean percent decreases in lipid parameters were similar for both cohorts, regardless of whether subjects remained at their initial dose or doubled their initial dose. At Week 8, on average, the percent change from baseline in LDL-C and TC was approximately 40% and 30%, respectively, over the range of exposures.</p><p>In a second open label, single arm study, 271 male and female HeFH children 6-15 years of age were enrolled and treated with atorvastatin for up to three years. Inclusion in the study required confirmed HeFH and a baseline LDL-C level &ge; 4 mmol/L (approximately 152 mg/dL). The study included 139 children at Tanner 1 developmental stage (generally ranging from 6-10 years of age). The dosage of atorvastatin (once daily) was initiated at 5 mg (chewable tablet) in children less than 10 years of age. Children age 10 and above were initiated at 10 mg atorvastatin (once daily). All children could titrate to higher doses to achieve a target of &lt; 3.35 mmol/L LDL-C. The mean weighted dose for children aged 6 to 9 years was 19.6 mg and the mean weighted dose for children aged 10 years and above was 23.9 mg.</p><p>The mean (+/- SD) baseline LDL-C value was 6.12 (1.26) mmol/L which was approximately 233 (48) mg/dL. See table 3 below for final results.</p><p>The data were consistent with no drug effect on any of the parameters of growth and development (i.e., height, weight, BMI, Tanner stage, Investigator assessment of Overall Maturation and Development) in paediatric and adolescent subjects with HeFH receiving atorvastatin treatment over the 3 year study. There was no Investigator-assessed drug effect noted in height, weight, BMI by age or by gender by visit.</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td colspan="7" style="vertical-align:top"><p><strong>TABLE 3.&nbsp;<u>Lipid-lowering Effects of Atorvastatin in Adolescent Boys and Girls with Heterozygous Familial Hypercholesterolemia (mmol/L)</u></strong></p></td></tr><tr><td style="vertical-align:top"><p>Timepoint</p></td><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>TC (S.D.)</p></td><td style="vertical-align:top"><p>LDL-C (S.D.)</p></td><td style="vertical-align:top"><p>HDL-C (S.D.)</p></td><td style="vertical-align:top"><p>TG (S.D.)</p></td><td style="vertical-align:top"><p>Apo B (S.D.)#</p></td></tr><tr><td style="vertical-align:top"><p>Baseline</p></td><td style="vertical-align:top"><p>271</p></td><td style="vertical-align:top"><p>7.86(1.30)</p></td><td style="vertical-align:top"><p>6.12(1.26)</p></td><td style="vertical-align:top"><p>1.314(0.2663)</p></td><td style="vertical-align:top"><p>0.93(0.47)</p></td><td style="vertical-align:top"><p>1.42(0.28)**</p></td></tr><tr><td style="vertical-align:top"><p>Month 30</p></td><td style="vertical-align:top"><p>206</p></td><td style="vertical-align:top"><p>4.95(0.77)*</p></td><td style="vertical-align:top"><p>3.25(0.67)</p></td><td style="vertical-align:top"><p>1.327(0.2796)</p></td><td style="vertical-align:top"><p>0.79(0.38)*</p></td><td style="vertical-align:top"><p>0.90(0.17)*</p></td></tr><tr><td style="vertical-align:top"><p>Month 36/ET</p></td><td style="vertical-align:top"><p>240</p></td><td style="vertical-align:top"><p>5.12(0.86)</p></td><td style="vertical-align:top"><p>3.45(0.81)</p></td><td style="vertical-align:top"><p>1.308(0.2739)</p></td><td style="vertical-align:top"><p>0.78(0.41)</p></td><td style="vertical-align:top"><p>0.93(0.20)***</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>TC= total cholesterol; LDL-C = low density lipoprotein cholesterol-C; HDL-C = high density lipoprotein cholesterol-C; TG = triglycerides; Apo B = apolipoprotein B; &ldquo;Month 36/ET&rdquo; included final visit data for subjects who ended participation prior to the scheduled 36 month timepoint as well as full 36 month data for subjects completing the 36 month participation; &ldquo;*&rdquo;= Month 30 N for this parameter was 207; &ldquo;**&rdquo;= Baseline N for this parameter was 270; &ldquo;***&rdquo; = Month 36/ET N for this parameter was 243; &ldquo;#&rdquo;=g/L for Apo B.</p></td></tr></tbody></table><p><em>Heterozygous Familial Hypercholesterolaemia in Paediatric Patients aged 10-17 years old</em></p><p>In a double-blind, placebo controlled study followed by an open-label phase, 187 boys and postmenarchal girls 10-17 years of age (mean age 14.1 years) with heterozygous familial hypercholesterolaemia (FH) or severe hypercholesterolaemia were randomised to atorvastatin (n=140) or placebo (n=47) for 26 weeks and then all received atorvastatin for 26 weeks. The dosage of atorvastatin (once daily) was 10 mg for the first 4 weeks and up-titrated to 20 mg if the LDL-C level was &gt;3.36 mmol/L. Atorvastatin significantly decreased plasma levels of total-C, LDL-C, triglycerides, and apolipoprotein B during the 26 week double-blind phase. The mean achieved LDL-C value was 3.38 mmol/L (range: 1.81-6.26 mmol/L) in the atorvastatin group compared to 5.91 mmol/L (range: 3.93-9.96 mmol/L) in the placebo group during the 26-week double-blind phase.</p><p>An additional paediatric study of atorvastatin versus colestipol in patients with hypercholesterolaemia aged 10-18 years demonstrated that atorvastatin (N=25) caused a significant reduction in LDL-C at week 26 (p&lt;0.05) compared with colestipol (N=31).</p><p>A compassionate use study in patients with severe hypercholesterolaemia (including homozygous hypercholesterolaemia) included 46 paediatric patients treated with atorvastatin titrated according to response (some subjects received 80 mg atorvastatin per day). The study lasted 3 years: LDL-cholesterol was lowered by 36%.</p><p>The long-term efficacy of atorvastatin therapy in childhood to reduce morbidity and mortality in adulthood has not been established.</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with atorvastatin in children aged 0 to less than 6 years in the treatment of heterozygous hypercholesterolaemia and in children aged 0 to less than 18 years in the treatment of homozygous familial hypercholesterolaemia, combined (mixed) hypercholesterolaemia, primary hypercholesterolaemia and in the prevention of cardiovascular events (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Atorvastatin is rapidly absorbed after oral administration; maximum plasma concentrations (C<sub>max</sub>) occur within 1 to 2 hours. Extent of absorption increases in proportion to atorvastatin dose. After oral administration, atorvastatin film-coated tablets are 95% to 99% bioavailable compared to the oral solution. The absolute bioavailability of atorvastatin is approximately 12% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%. The low systemic availability is attributed to presystemic clearance in gastrointestinal mucosa and/or hepatic first-pass metabolism.</p><p><u>Distribution</u></p><p>Mean volume of distribution of atorvastatin is approximately 381 l. Atorvastatin is &ge; 98% bound to plasma proteins.</p><p><u>Biotransformation</u></p><p>Atorvastatin is metabolised by cytochrome P450 3A4 to ortho- and parahydroxylated derivatives and various beta-oxidation products. Apart from other pathways these products are further metabolised via glucuronidation. In vitro, inhibition of HMG-CoA reductase by ortho- and parahydroxylated metabolites is equivalent to that of atorvastatin. Approximately 70% of circulating inhibitory activity for HMG-CoA reductase is attributed to active metabolites.</p><p><u>Elimination</u></p><p>Atorvastatin is eliminated primarily in bile following hepatic and/or extrahepatic metabolism. However, atorvastatin does not appear to undergo significant enterohepatic recirculation. Mean plasma elimination half-life of atorvastatin in humans is approximately 14 hours. The half-life of inhibitory activity for HMG-CoA reductase is approximately 20 to 30 hours due to the contribution of active metabolites.</p><p>Atorvastatin is a substrate of the hepatic transporters, organic anion-transporting polypeptide 1B1 (OATP1B1) and 1B3 (OATP1B3) transporter. Metabolites of atorvastatin are substrates of OATP1B1. Atorvastatin is also identified as a substrate of the efflux transporters multi-drug resistance protein 1 (MDR1) and breast cancer resistance protein (BCRP), which may limit the intestinal absorption and biliary clearance of atorvastatin.</p><p><u>Special populations</u></p><p><em>Elderly</em></p><p>Plasma concentrations of atorvastatin and its active metabolites are higher in healthy elderly subjects than in young adults while the lipid effects were comparable to those seen in younger patient populations.</p><p><em>Paediatric population</em></p><p>In an open-label, 8-week study, Tanner Stage 1 (N=15) and Tanner Stage &ge;2 (N=24) paediatric patients (ages 6-17 years) with heterozygous familial hypercholesterolemia and baseline LDL-C &ge; 4 mmol/L were treated with 5 or 10 mg of chewable or 10 or 20 mg of film-coated atorvastatin tablets once daily, respectively. Body weight was the only significant covariate in atorvastatin population PK model. Apparent oral clearance of atorvastatin in paediatric subjects appeared similar to adults when scaled allometrically by body weight. Consistent decreases in LDL-C and TC were observed over the range of atorvastatin and o-hydroxyatorvastatin exposures.</p><p><em>Gender</em></p><p>Concentrations of atorvastatin and its active metabolites in women differ from those in men (Women: approx. 20% higher for C<sub>max</sub>&nbsp;and approx. 10% lower for AUC). These differences were of no clinical significance, resulting in no clinically significant differences in lipid effects among men and women.</p><p><em>Renal impairment</em></p><p>Renal disease has no influence on the plasma concentrations or lipid effects of atorvastatin and its active metabolites.</p><p><em>Hepatic impairment</em></p><p>Plasma concentrations of atorvastatin and its active metabolites are markedly increased (approx. 16-fold in C<sub>max</sub>&nbsp;and approx. 11-fold in AUC) in patients with chronic alcoholic liver disease (Child-Pugh B).</p><p><em>SLOC1B1 polymorphism</em></p><p>Hepatic uptake of all HMG-CoA reductase inhibitors including atorvastatin, involves the OATP1B1 transporter. In patients with SLCO1B1 polymorphism there is a risk of increased exposure of atorvastatin, which may lead to an increased risk of rhabdomyolysis (see section 4.4). Polymorphism in the gene encoding OATP1B1 (SLCO1B1 c.521CC) is associated with a 2.4-fold higher atorvastatin exposure (AUC) than in individuals without this genotype variant (c.521TT). A genetically impaired hepatic uptake of atorvastatin is also possible in these patients. Possible consequences for the efficacy are unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Atorvastatin was negative for mutagenic and clastogenic potential in a battery of 4 in vitro tests and 1 in vivo assay. Atorvastatin was not found to be carcinogenic in rats, but high doses in mice (resulting in 6-11fold the AUC0-24h reached in humans at the highest recommended dose) showed hepatocellular adenomas in males and hepatocellular carcinomas in females.</p><p>There is evidence from animal experimental studies that HMG-CoA reductase inhibitors may affect the development of embryos or foetuses. In rats, rabbits and dog&rsquo;s atorvastatin had no effect on fertility and was not teratogenic, however, at maternally toxic doses foetal toxicity was observed in rats and rabbits. The development of the rat offspring was delayed and post-natal survival reduced during exposure of the dams to high doses of atorvastatin. In rats, there is evidence of placental transfer. In rats, plasma concentrations of atorvastatin are similar to those in milk. It is not known whether atorvastatin or its metabolites are excreted in human milk.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Microcrystalline Cellulose 180 mm</p><p>Calcium Carbonate 90% Granules</p><p>Lactose monohydrate (Super -TAB Spray dried</p><p>Hydroxypropyl cellulose (klucel EF)</p><p>Croscarmellose sodium</p><p>Magnesium Stearate</p><p>Hydroxypropyl methyl cellulose Type 2920 (Methocel E5)</p><p>Titanium dioxide</p><p>Polyethylene Glycol 400</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Three years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;Do not store above 30&ordm;C, protected from humidity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>TORVACOL 40 Tablets are packed in boxes of 30 Tablets blistered in aluminium foil.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Any unused product or waste material should be disposed of accordance with local requirements.&nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Jordanian Pharmaceutical Manufacturing Co. Ltd.
PO Box 151
Um Al-Amad 16197
Jordan

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                September 2023.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>